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ABSTRACT 
 
The purpose of this study was to assess fear of cancer recurrence (FCR) in breast cancer 
survivors returning for regularly scheduled follow-up mammograms.  FCR was hypothesized to 
increase prior to the mammogram, decrease from immediately pre- to immediately post-
mammogram, and then increase following the mammogram.  Based on the cognitive-behavioral 
model (CBM) of health anxiety, greater perceived risk of recurrence, worse perceived 
consequences of a recurrence, lower coping self-efficacy, and more engagement in reassurance-
seeking behaviors were hypothesized to be associated with greater FCR in each time segment.  
Finally, exploratory analyses evaluated the various trajectories in FCR over time using growth 
mixture modeling and the CBM to predict class membership.  The sample comprised 161 women 
who completed treatment for stage 0-IIIA breast cancer between 6 and 36 months previously.  
Participants completed the following measures at least 31 days prior to the scheduled 
mammogram:  perceived risk and perceived consequences of breast cancer recurrence, treatment 
efficacy beliefs, coping self-efficacy, and reassurance seeking behaviors.  Participants reported 
FCR at one month, one week, and immediately prior to the mammogram as well as one month, 
one week, and immediately after the mammogram using visual analogue scales (VAS) to rate 
anxiety and worry about cancer recurrence, the Cancer Worry Scale (CWS), and the Fear of 
Cancer Recurrence Inventory (FCRI).  State anxiety and reassurance post-mammogram were 
also assessed.  FCR significantly changed over time with increases in CWS scores prior to the 
mammogram, a significant decline on the VAS observed immediately following receipt of 
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results, and a significant increase on the VAS, and decrease in reassurance during the month 
following the mammogram.  The CBM did not significantly predict change in FCR over time, 
but certain variables did predict fluctuations including coping-self efficacy and perceived risk in 
the expected directions.  Finally, growth mixture models revealed two classes, high-FCR and 
low-FCR, which were predicted by the CBM.  These study findings support the use of the CBM 
in predicting which cancer survivors experience greater FCR and indicates that CBM-driven 
interventions may prove beneficial for reducing distressing FCR. 
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INTRODUCTION 
 
Fear of cancer recurrence (FCR) is emerging as an important topic in cancer survivorship 
research.  FCR is broadly defined as the fear or worry that cancer will return or progress in the 
same organ or in another part of the body (Simard & Savard, 2009; Vickberg, 2003).  To date, 
numerous studies have reported that the majority of cancer survivors endorse at least some FCR, 
even several years after successful cancer treatment (Baker, Denniston, Smith, & West, 2005; 
Deimling, Bowman, Sterns, Wagner, & Kahana, 2006; Herschbach et al., 2004; Lampic et al., 
1994; Mehnert, Berg, Henrich, & Herschbach, 2009; Schroevers, Ranchor, & Sanderman, 2006; 
van den Beuken-van Everdingen et al., 2008).  For example, in a study of women with breast 
cancer who had completed treatment, 39% rated FCR as a dominant concern and nearly half felt 
that they had moderate-to-high unmet needs about addressing these fears (Stanton et al., 2005).  
Even long-term survivors continue to have fears about their health.  Roughly one third of breast 
cancer survivors averaging ten years since diagnosis reported worries about a future recurrence, 
concerns that their current physical symptoms may signal a recurrence, concerns about 
developing another type of cancer, or worry about future diagnostic tests (Deimling et al., 2006).   
While some FCR may be adaptive, higher levels of FCR may be problematic.  Greater 
FCR has consistently been found to be related to worse quality of life (Baker et al., 2005; Hart, 
Latini, Cowan, Carroll, & CaPSURE Investigators, 2008; Mehnert et al., 2009; Simard & 
Savard, 2009; Skaali et al., 2009; van den Beuken-van Everdingen et al., 2008), heightened 
anxiety (Deimling et al., 2006; Humphris et al., 2003; Llewellyn, Weinman, McGurk, & 
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Humphris, 2008; Rothrock, Matthews, Sellergren, Fleming, & List, 2004; Simard & Savard, 
2009; Skaali et al., 2009), more intrusive thoughts about illness (Mehnert et al., 2009; Simard & 
Savard, 2009; Simard, Savard, & Ivers, 2010; Skaali et al., 2009), more depressive symptoms 
(Deimling et al., 2006; Humphris et al., 2003; Simard & Savard, 2009; Skaali et al., 2009), and 
more post-traumatic stress symptoms (Mehnert et al., 2009; Simard & Savard, 2009).   
Information about the course of FCR is limited since most previous studies have used 
cross-sectional research designs.  Among the few previous longitudinal studies, most span a time 
period from soon after diagnosis to up to 15 months post-treatment.  These studies have reported 
that levels of FCR remain relatively stable following diagnosis (Humphris & Rogers, 2004; 
Llewellyn et al., 2008; Stanton, Danoff-burg, & Huggins, 2002).  Another study following head 
and neck cancer survivors averaging four years after treatment found no change in FCR over a 
two-year time interval (Humphris et al., 2003).  Only one study to date has noted significant 
change in FCR over time.  Rabin, Leventhal and Goodin (2004) found evidence for a significant 
decrease in FCR from the period during chemotherapy to one month after completion of 
chemotherapy.  In general, previous longitudinal studies have not focused on discrete time 
periods to detect subtle fluctuations in FCR over time and have not assessed FCR during key 
medical events post-treatment (i.e., cancer screening appointments).  Cancer survivors report 
anecdotally that the repeated examinations and consultations post-treatment can elicit heightened 
anxiety and FCR, especially leading up to procedures, exams, or awaiting receipt of testing 
results (Gil et al., 2004; Okazaki et al., 2009).  Hence, more research on the longitudinal course 
of FCR over time is warranted.   
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Screening Anxiety  
 Medical screening exams provide an interesting opportunity to study temporal 
fluctuations in FCR.  Typically, patients report experiencing a decrease in anxiety and worry 
immediately following receipt of negative test results following examinations such as 
gastroscopy, endoscopy, and procedures conducted during general practitioner visits (i.e., blood 
test results, physical examinations, etc.) to identify the source of common health complaints 
(Laasko, Niemi, Grönroos, & Karlsson, 2008; Lucock, Morley, White, & Peake, 1997; Quadri & 
Vakil, 2003).  However, longer-term follow-up assessments often reveal that the reassuring 
effect of the test result is short-lived, with patients in several studies demonstrating increases in 
anxiety or worry and decreases in reassurance as soon as one day after receiving the results 
(Donkin et al., 2006; Lucock et al., 1997; Rimes & Salkovskis, 2002).  There is also evidence of 
individual differences in the pattern of anxiety over time, with some patients reporting no change 
over time (Howard et al., 2005; Laasko et al., 2008; Quadri & Vakil, 2003; Rimes & Salkovskis, 
2002), and others reporting increases in anxiety immediately following receipt of negative 
results (Laasko et al., 2008; Rimes & Salkovskis, 2002; Rimes, Salkovskis, Jones, & Lucassen, 
2006). 
Research assessing anxiety and worry related to screening mammograms in women with 
no history of cancer has also revealed differing patterns of anxiety.  Some studies assessing 
women at various times before and after a mammogram have found that anxiety is low overall 
and does not change significantly over time (Brunton, Jordan, & Campbell, 2005; Scaf-Klomp, 
Sanderman, van de Wiel, Otter, & van de Heuvel, 1997; Sutton, Saidi, Bickler, & Hunter, 1995).  
However, a study that measured cancer worry and risk perceptions, rather than anxiety alone, 
found that both cancer worry and cancer risk perceptions decrease from the period before the 
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mammogram to two months after (Absetz, Aro, & Sutton, 2003).  Further, illness beliefs such as 
perceived susceptibility to cancer predicted differences in the trajectory of distress over time.  
Those with high perceived susceptibility experienced decreases in depressive symptoms from 
pre-screening to two months after screening with a return to pre-screening levels by one year 
after screening.  In contrast, there was no change in depressive symptoms for the low 
susceptibility group (Absetz et al., 2003).  Another study examined differences between women 
who felt reassured following normal mammogram screening results and those who did not 
(Meechan, Collins, Moss-Morris, & Petrie, 2005).  Findings indicated that women who were not 
reassured were more likely to have reported breast changes prior to the mammogram, perhaps 
suggesting that they were still concerned about their medically unexplained breast symptoms 
(Meechan et al., 2005).  The lack of consistent findings for changes in anxiety and cancer worry 
before and after mammograms in healthy women may be due to the fact that no available studies 
have assessed women intensively over time.  In fact, all of these studies had assessments 
occurring three or more months apart, making changes in anxiety related to mammography 
screening more difficult to detect, especially if such anxiety is short-lived. 
A limited number of studies have examined anxiety related to mammography in women 
who are at objectively greater risk for cancer, such as women with family or personal histories of 
breast cancer.  In a systematic review comparing women with and without a family history of 
breast cancer, those with a family history had significantly higher anxiety than those with no 
family history during the time of the mammogram and up to six weeks after (Watson, 
Henderson, Brett, Bankhead, & Austoker, 2005).  Longitudinal studies of cancer patients 
attending routine medical follow-up visits have found some evidence of fluctuations in anxiety 
following these appointments.  Breast cancer patients attending routine follow-up visits 
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experienced low anxiety overall, but showed significant increases in anxiety between a few days 
to three weeks after the visit (Lampic et al., 1994).  Unfortunately, existing longitudinal studies 
of cancer survivors attending follow-up medical visits have not assessed FCR with validated 
measures and have not assessed FCR or anxiety leading up to the appointments to determine if 
there are fluctuations in these concerns in anticipation of the visit. 
Predictors of Fear of Cancer Recurrence  
Despite how commonly FCR is reported, there has been relatively little research aimed at 
identifying predictors of or risk factors for FCR.  Interestingly, FCR has typically not been found 
to be related to objective prognostic features of the cancer.  Along these lines, several studies 
have not found a relationship between the magnitude of FCR and factors such as time since 
diagnosis (McGinty, Goldenberg, & Jacobsen, 2012; McGinty, Simard, Savard, & Jacobsen, 
2010; Simard & Savard, 2009; Skaali et al., 2009), time since treatment completion (Humphris et 
al., 2003; McGinty et al., 2010; van den Beuken-van Everdingen et al., 2008), past treatment 
(McGinty et al., 2010; McGinty et al., 2012), or cancer stage (Llewellyn et al., 2008; Rabin et al., 
2004).  However, certain demographic characteristics have be linked to heightened FCR, 
including younger age (Deimling et al., 2006; Humphris et al., 2003; Lofters, Juffs, Pond, & 
Tannock, 2002; Mehnert et al., 2009; McGinty et al., 2012; Mullens, McCaul, Erickson, & 
Sandgren, 2004; Simard & Savard, 2009; Stanton et al., 2005; van den Beuken-van Everdingen 
et al., 2008) and lower education (Lofters et al., 2002; Skaali et al., 2009).  In addition, several 
studies have found links between psychosocial variables and FCR.  For example, higher 
perceived risk of cancer was found to be related to greater FCR in breast cancer survivors 
(McGinty et al., 2010; McGinty et al., 2012; Rothrock et al., 2004).     
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Relevant Theories 
To date, most studies have not utilized relevant theories that might inform research into 
prediction of FCR in cancer survivors.  Two such theories are Leventhal’s common sense model 
of illness representations (CSM; Leventhal, Diefenbach, & Leventhal, 1992) and the cognitive-
behavioral approach to health anxiety (Salkovskis & Warwick, 1986; Warwick, 1989).  The 
CSM describes how cognitive appraisals of illness can influence both distress and health 
behaviors and has been used successfully to predict heightened distress in various medical 
populations (Haggar & Orbell, 2003).  According to the model, health information is interpreted 
along a number of dimensions to form cognitive and emotional illness representations that then 
influence how individuals chose to cope with various health threats, depending on the 
interpretation.  Key illness representations are beliefs about the cause, consequences, identity, 
emotional impact, timeline, and cyclic or stable course of an illness as well as beliefs about 
personal control and treatment efficacy to cure or reduce the impact of the illness (Leventhal et 
al., 1992; Leventhal, Leventhal, & Contrada, 1998; Moss-Morris et al., 2002).  A meta-analytic 
review found that, in general, more negative illness representations predicted worse emotional 
distress in patients with a variety of medical conditions (Haggar & Orbell, 2003). 
Longitudinal studies assessing distress in women with cancer have found that distress is 
predicted by illness perceptions including perceived timeline of the cancer, identifying more 
physical symptoms as related to the cancer, and feelings of personal control over the course of 
the cancer (Henselmans et al., 2010; Millar, Purushotham, McLatchie, George, & Murray, 2005; 
Ward, Viergutz, Tormey, deMuth, & Paulen, 1992).  Two recent studies have found partial 
support for the use of Leventhal’s model in predicting FCR in survivors of various cancers.  In a 
study of patients treated for head and neck cancer, more negative perceived consequences of a 
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recurrence and a worse emotional representation of cancer were related to greater FCR 
(Llewellyn et al., 2008).  In a study of women treated for breast cancer, conceptualizing cancer 
as a chronic or cyclic condition, rather than as an acute condition, was related to greater FCR 
(Rabin et al., 2004).   
The cognitive-behavioral model of health anxiety is similar to the CSM in that it 
examines the impact of key illness beliefs on health anxiety and distress.  It also addresses the 
impact of behaviors (i.e., reassurance seeking, checking bodily status) that may serve to maintain 
and reinforce elevated health anxiety (Salkovskis & Warwick, 1986; Salkovskis & Warwick, 
2001; Warwick, 1989).  According to the model, existing perceptions about health and relevant 
health threats influence the degree to which individuals become anxious about their health.  If 
anxiety is elicited by beliefs about their health, then the individual may engage in behaviors to 
temporarily reduce their anxiety.  Because these behaviors do not typically change the inherent 
risk of health problems or change the health beliefs permanently, they serve to reinforce the 
anxiety brought on by the illness beliefs and lead to increased anxiety in the long-term.  Key 
illness beliefs in this model are perceived risk of the illness, perceived severity of the 
consequences of the illness, perceived ability to cope with the illness, and perceived 
effectiveness of available treatments to cure or control the illness (Warwick, 1989; Salkovskis & 
Warwick, 2001). 
Originally, the cognitive-behavioral model was proposed to identify predictors of 
hypochondriasis and health anxiety (Salkovskis & Warwick, 1986; Warwick, 1989).  More 
recently it has been used to study changes in health anxiety in individuals undergoing various 
medical screening consultations (Hadjistavropoulos, Craig, & Hadjistavropoulos, 1998; Rimes & 
Salkovskis, 2002; Rimes et al., 2006).  In a study of healthy women undergoing bone mineral 
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density screening, illness beliefs about the severity of osteoporosis, perceived risk, ability to 
cope, and treatment efficacy were predictive of later anxiety.  Indeed, perceived severity of 
osteoporosis was more strongly related to later anxiety than the actual results of the screening 
(Rimes & Salkovskis, 2002).  Additional findings focused on predicting changes in health-
related worry and anxiety over time following screening and compared those with high or low 
general health anxiety.  Those with high health anxiety in general experienced reduced anxiety 
immediately following good news about their results, but their anxiety, worry about 
osteoporosis, and perceived risk returned to pre-screening levels after 14 months (Rimes & 
Salkovskis, 2002).  In another study using this model, Rimes et al. (2006) assessed anxiety in 
healthy individuals with family histories of cancer before and six months after genetic 
counseling about cancer risk.  Similar to their previous results (Rimes & Salkovskis, 2002), the 
authors found that objective risk factors were unrelated to changes in anxiety over time; 
however, illness beliefs including higher perceived risk, perceived coping abilities, and more 
severe perceived consequences of cancer, were related to health anxiety (Rimes et al., 2006).  
Again, they found that patterns of anxiety during health screening were predicted by having 
either high or low general health anxiety (Rimes et al., 2006).  Those high in health anxiety 
showed a reduction in perceived risk of cancer and anxiety at six months, however, those with 
low health anxiety experienced no change in perceived risk or anxiety over time (Rimes et al., 
2006).  As demonstrated by these studies, the cognitive-behavioral model of health anxiety has 
been shown to not only predict health anxiety and cancer-specific anxiety, but also fluctuations 
in health anxiety over time following screening and consultations.  Because FCR can be 
conceptualized as cancer-specific health anxiety, FCR may also be predicted by the cognitive-
behavioral factors associated with fluctuations in health anxiety.  
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Current Study 
There are several important gaps in the existing FCR research literature.  First, there are 
few studies that have examined theory-driven predictors of FCR in prospective, longitudinal 
designs.  Available studies have typically focused on psychological morbidity associated with 
FCR, but have rarely examined the sources of FCR itself.  Those that have done so have focused 
on cognitive, but not behavioral predictors of FCR.  Further, no research to date has assessed 
FCR intensively to determine whether there are fluctuations surrounding medical exams.  
Specifically, it is not clear to what degree FCR changes as a result of important cancer-related 
events, such as the receipt of cancer screening results following the completion of active cancer 
treatment.  Along these lines, no study has documented FCR in relation to follow-up 
mammography screening in breast cancer survivors to determine if these screening appointments 
elicit heightened FCR and anxiety.   
With these considerations in mind, the purpose of this study is to examine patterns of 
change in fear of cancer recurrence before and after regularly scheduled mammograms in breast 
cancer survivors.  Breast cancer survivors who have completed treatment will be surveyed 
longitudinally to examine the pattern of FCR over time.  Assessments will be completed at the 
following times:  one month prior to the mammogram (T1), one week prior to the mammogram 
(T2), immediately before the mammogram (T3), immediately after receipt of results (T4), one 
week after receipt of results (T5), and one month after receipt of results (T6).  Participants will 
also report on their anxiety level, cognitions, and behaviors to evaluate how these are related to 
FCR. 
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Hypotheses. The following hypotheses will be tested: 
 1) There will be a significant increase in fear of recurrence over the period before participants 
undergo a routine mammogram (T1 to T3).   
 2) There will be a significant decrease in fear of recurrence over the period from shortly before 
to shortly after participants receive negative mammogram results (T3 to T4).   
 3) There will be a significant increase in fear of recurrence over the period of time after 
participants received negative mammogram results (T4 to T6).   
In addition to these hypotheses, we will examine predictors of individual differences in 
fear of recurrence over time.  Following the cognitive-behavioral model of health anxiety, it is 
hypothesized that greater perceived risk of breast cancer recurrence, worse perceived severity of 
breast cancer recurrence, lower perceived efficacy of breast cancer treatment, lower self-efficacy 
for coping with cancer recurrence, and more reassurance seeking behaviors will predict:   
4) greater increase in fear of recurrence before the mammogram (T1 to T3);   
5) less reduction in fear of recurrence immediately following receipt of negative 
mammogram results (T3 to T4); and 
6) greater increase in fear of recurrence following receipt of negative mammogram 
results (T4 to T6).   
Finally, exploratory analyses will be conducted to determine whether distinct trajectories for 
changes in fear of recurrence over time can be identified (T1 to T6) and whether cognitive and 
behavioral factors predict which trajectory patients exhibit.  Additional exploratory analyses will 
examine if there is significant change in state anxiety before and after the mammogram (T1 to 
T6), and reassurance following the mammogram (T4 to T6). 
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METHOD 
 
Participants 
Eligibility criteria.  Breast cancer survivors scheduled for regular follow-up 
mammography at Moffitt Cancer Center were approached to participate.  Eligibility criteria 
were:  age greater than or equal to 18 years, diagnosed with stage 0 to IIIA breast cancer, 
completed primary treatment for breast cancer within the past 3 years, able to read and speak 
English, had access to internet, and able to provide informed consent.  Breast cancer survivors 
were excluded if they had a history of other cancers (except non-melanoma skin cancer) or 
evidence of disease recurrence.  Statistical analyses only include participants who received 
negative mammography results.  Participants who were recalled for further screening or 
additional tests after their mammogram were excluded from analyses. 
Procedure 
Patients were screened for eligibility via medical chart review.  Eligible patients were 
contacted via mail with a letter from their Moffitt physician inviting them to participate and 
providing an option to decline via postcard.  Patients who did not decline were called to confirm 
their mammography appointment was approaching.  They were then mailed the consent form and 
login information to complete the initial questionnaire online five weeks before their scheduled 
mammogram.  Because timing of assessments were presumed to detect changes in FCR, online 
surveys were used in place of mail-in surveys to ensure that participants were completing 
assessments that occurred outside the clinic on time.  Participants completed questionnaires at 
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seven time points:  a baseline questionnaire with clinical, demographic, and psychological 
predictors completed between 38 and 31 days prior to the mammogram appointment (T0), and 
six follow-up surveys assessing FCR and state anxiety one month prior to the scheduled 
mammogram (T1), one week prior to the scheduled mammogram (T2), immediately prior to 
their mammography appointment (T3), immediately following receipt of mammography results 
(T4), one week after receipt of results (T5), and one month after receipt of results (T6). The T0, 
T1, T2, T5, and T6 questionnaires were completed online.  Women received reminder emails and 
phone calls to alert them to complete the T1, T2, T5 and T6 questionnaires within 2 days of the 
target date.  
The T3 and T4 questionnaires were completed on the day of the mammography 
appointment at the clinic.  On this day, patients were met by a member of the research team in 
the clinic waiting room to complete the T3 questionnaire prior to being called to undergo their 
mammogram.  At Moffitt Cancer Center, all breast cancer patients receive a diagnostic 
mammogram which entails two views on each breast (or two views on the contralateral breast 
only in the case of mastectomy patients) and is completed within 15 to 20 minutes.  After the 
mammogram is completed, patients are escorted to a different waiting area where they await the 
receipt of the results approximately two hours later.  Results are explained by their treating 
surgeon or medical oncologist the same day as the exam before patients leave the clinic.  
Immediately after the patients received the results, they completed the T4 questionnaire in the 
clinic waiting area.   
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Measures 
Demographic characteristics.  A standardized self-report form was used to collect the 
following information at T0:  age, height, weight, race, ethnicity, marital status, income, 
education, and menopausal status.   
Clinical characteristics.  The following clinical characteristics were assessed via 
medical chart review:  stage at diagnosis, treatment(s) received (any surgeries or adjuvant 
treatments, including on-going treatments such as hormone therapy or herceptin), time since 
diagnosis, and time since treatment completion.  
Perceived risk.  Perceived risk of a cancer recurrence was assessed at T0 by obtaining 
participants’ estimates of their absolute and comparative risk using items adapted from prior 
research (Valdimarsdottir et al., 1995).  To assess absolute risk, participants were asked, “How 
likely do you think you are to have breast cancer again during your lifetime?” and to assess 
comparative risk, they were asked, “What do you think your chances are of having breast cancer 
again in your lifetime compared to other women your age with breast cancer who received the 
same treatment for the same type of breast cancer?”.  Response options range from 1 (extremely 
unlikely) to 6 (extremely likely) for the absolute risk item and from 1 (much higher) to 5 (much 
lower) for the comparative risk item.  Based on the correlation observed in the present study (r = 
-.42) and methods used in other studies (McGinty et al., 2012), absolute and comparative risk 
estimates were converted to the same metric by finding a common product and then summed to 
create a total perceived risk score. 
Perceived severity.  The Consequences Subscale of the Revised Illness Perception 
Questionnaire (Moss-Morris et al., 2002) was administered at T0 to assess perceived severity of 
the consequences of a breast cancer recurrence.  All items were adapted to refer to a “recurrence 
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of breast cancer” as the target illness to be considered.  Items reflect the potential medical, social, 
financial, and psychological consequences of a breast cancer recurrence.  Participants were asked 
to indicate how much they agreed with each consequence on a scale ranging from 1 (strongly 
disagree) to 5 (strongly agree).  This measure showed acceptable psychometric properties in 
previous research (Moss-Morris et al., 2002).  Internal consistency was also acceptable for the 
current study sample (Cronbach’s α = .82). 
Coping self-efficacy beliefs.   The brief Cancer Behavior Inventory (CBI-B; Heitzmann 
et al., 2010) was administered at T0 to assess participants’ beliefs about their ability to cope with 
the possibility of a breast cancer recurrence.  The CBI-B is comprised of 16 items and measures 
patients’ confidence in providing self-care during cancer diagnosis, treatment, and recovery.  The 
original measure was adapted to measure patients’ confidence that they could follow common 
self-care practices in the event that their cancer returned.  Participants were asked to rate their 
confidence for maintenance of activities and independence, coping with side effects, positive 
attitude, seeking medical information, affective regulation, stress management and seeking 
support.  Response options are on a Likert scale ranging from 1 (not at all confident) to 9 (totally 
confident).  The original CBI and CBI-B demonstrated acceptable reliability in previous research 
and have been validated for use with cancer patients (Merluzzi et al., 2001; Heitzmann et al., 2010; 
Henselmans, Fleer, de Vries, Baas, Sanderman, & Ranchor, 2009).  This measure demonstrated 
acceptable internal consistency in this sample (Cronbach’s α = .92). 
Treatment efficacy beliefs.  Participants were asked several questions at T0 to assess 
their beliefs that available treatments would be effective in prolonging the lives of women who 
have a breast cancer recurrence.  Items were derived from a scale used to assess physician’s 
treatment efficacy beliefs for prostate cancer (Fowler et al., 1998).  Participants rated the extent 
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to which they believe that available treatment options can provide a survival benefit.  Five 
treatment options were assessed including surgery, chemotherapy, radiation, hormone therapy, 
and a combination of these treatments.  Response options range from 1 (definitely not) to 4 
(definitely).  This measure demonstrated acceptable internal consistency in the current sample 
(Cronbach’s α = .73). 
Reassurance-seeking behaviors.  Participants were asked at T0 to report self-checking 
behaviors using the 3-item reassurance-seeking behavior subscale of the Health Anxiety 
Questionnaire (HAQ; Lucock & Morley, 1996).  Items assess the frequency with which patients 
are performing informal exams of their own bodies, asking others about health concerns, and 
reading information about illnesses to determine if they are sick.  Response options are 1 (not at 
all or rarely), 2 (sometimes), 3 (often), and 4 (most of the time).  The HAQ has shown good 
reliability and validity in previous research (Lucock & Morley, 1996; Lucock, Morley, White, & 
Peake, 1997; Meechan et al., 2005; Quadri & Vakil, 2003).  The reassurance-seeking behavior 
subscale demonstrated relatively poor internal consistency in the current sample (Cronbach’s α = 
.56). 
Fear of cancer recurrence.  Participants completed three separate measures of fear of 
cancer recurrence.  One month prior to the scheduled mammogram (T1), the day of the 
mammogram (T3), and one month after the scheduled mammogram (T6), participants completed 
the Fear of Cancer Recurrence Inventory (FCRI), a self-report measure of cancer recurrence fear 
in the past month (Simard & Savard, 2009).  The FCRI consists of 42-items which can provide 
clinically meaningful information about the nature of FCR and yields scores for 7 subscales:  
triggers, severity, distress, functional impairments, insight, reassurance, and coping.  Scores from 
each subscale are summed to create the total score, with higher scores indicating greater fear of 
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cancer recurrence.  Preliminary validation of the English version of this measure demonstrated 
good psychometric properties similar to the original French version (Lebel et al., 2010; McGinty 
et al., 2010).  There was acceptable internal consistency for this measure across all study time 
points (Cronbach’s α ranged from .95 to .96). 
At T1, T2, T3, T5 and T6, participants also completed the Cancer Worry Scale (CWS), 
which was modified to apply to cancer patients’ concerns of a possible recurrence (Rabin et al., 
2004).  This measure assesses the frequency of recurrence worry over the course of the past 
week using the following response options: 1 (not at all or rarely), 2 (sometimes), 3 (often), and 
4 (a lot).  In a previous study, we found that the modified CWS is positively related to measures 
of psychological distress such as depression (r = .49) and negatively related to mental health (r = 
-.43) in breast cancer survivors (McGinty, Jacobsen, & Andrykowski, 2008).  Compared to 
lengthier measures like the FCRI, the modified CWS is easily keyed to shorter time periods and 
is brief enough to reduce participant burden, while still providing information about the 
frequency of FCR.  This measure showed acceptable internal consistency in the current sample 
across all time points (Cronbach’s α ranged from .83 to .86). 
Finally, at all assessment time points, participants completed two visual analogue scales 
(VAS) assessing the extent to which they were “worried about the possibility of a breast cancer 
recurrence” and “anxious about the possibility of a breast cancer recurrence” to provide 
measures of the magnitude of FCR.  Possible responses ranged from 0 (not at all worried) to 100 
(extremely worried) for the first item and 0 (not at all anxious) to 100 (extremely anxious) for the 
second.  Across all study time points, the two VAS items were closely related, with correlations 
ranging from r = .85 to r = .94. 
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Anxiety.  The Brief State-Trait Anxiety Inventory (STAI) was completed at T1 through 
T6 to assess state anxiety (Marteau & Bekker, 1992).  Participants indicated the degree to which 
they felt calm, tense, upset, relaxed, content, and worried at the time of the assessment using a 
scale of 1 (not at all), 2 (somewhat), 3 (moderately so), and 4 (very much so).  The brief STAI 
has demonstrated excellent psychometric properties in several populations, including cancer 
patients (Henselmans et al., 2010; Marteau & Bekker, 1992).  There was acceptable internal 
consistency across all study time points (Cronbach’s α ranged from .74 to .90). 
Reassurance.  Patients’ subjective experience of reassurance after receipt of 
mammography results was assessed at each time point after the mammography appointment (i.e., 
T4 to T6).  Participants completed two items adapted from a reassurance scale used in previous 
research of patients following cardiopulmonary stress test results (Donkin et al., 2006).  The first 
item assesses overall sense of reassurance:  “The extent to which you were reassured by the 
results of your most recent mammogram” and response options are on a scale from 0 (not 
reassured at all) to 10 (completely reassured).  The second item assesses the desire for additional 
testing:  “The extent to which you believe that you should have additional testing to rule out the 
possibility of a breast cancer recurrence” with response options ranging from 0 (strongly 
disagree) to 10 (strongly agree).  Because these items were only moderately correlated, (r = .35 
to r = .51 across all time points), they were examined separately in subsequent analyses. 
Statistical Analyses 
The first three hypotheses predict significant change in FCR during the period of time 
leading up to the mammogram (hypothesis 1), from immediately before to immediately after 
receipt of results (hypothesis 2), and during the period of time following receipt of results 
(hypothesis 3).  To test for significant change in FCR over time, a series of unconditional growth 
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curve models using SAS PROC MIXED were conducted for each of these segments of time:  T1 
to T3 and T4 to T6.  First, fully unconditioned models were fit to the data to estimate the average 
FCR (intercept) followed by growth curve models which add time as a predictor of both initial 
FCR and change in FCR over time (slope).  Significant effects for time indicate significant 
change in FCR over time.  Repeated measures ANOVAs were used to test change between any 
time point with fewer than three measurements.  The average of the two VAS measures was used 
as the primary dependent measure for all analyses.  To test whether the type of FCR measure 
impacts results and to demonstrate reproducibility of results, analyses included the FCRI and 
modified CWS as secondary outcomes for those analyses where multiple measures of FCR are 
available across the different times.  Because two of the time segments include more than two 
assessment points, both linear and quadratic curves were examined for hypothesis 1 and 3.  
Additional exploratory analyses examined change in state anxiety (T1 to T3, T3 to T4, and T4 to 
T6) and change in reported reassurance following the mammogram (T4 to T6) using similar 
procedures for repeated measures ANOVAs and growth curve modeling outlined above. 
Next, relevant predictors of FCR over time were assessed to test hypotheses 4, 5, and 6.  
Residualized change scores were computed between the initial FCR score and the final FCR 
score for each time segment (i.e., T1 to T3, T3 to T4, T4 to T6), and used as the dependent 
variable in a multiple hierarchical regression analysis.  Univariate analyses were first conducted 
to examine interrelationships between FCR at each time point and demographic, clinical, and 
cognitive-behavioral variables to determine which variables were entered into the hierarchical 
regression.  The initial FCR score was entered on the first step to predict the final FCR score for 
that particular time segment, creating a residualized change score.  Demographic and clinical 
variables significantly related to FCR at any time point were entered on the second step in the 
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hierarchical regression.  Relevant cognitive-behavioral predictors were entered on the third step.  
A significant change in the variation explained between step 2 and step 3 would support the 
hypotheses that cognitive-behavioral variables predict change in FCR over time after controlling 
for demographic and clinical factors.  
Finally, growth mixture model analysis (Muthén, 2004) was conducted using Mplus 
Version 7 to determine whether there are multiple trajectories across all the time points.  The 
analyses require running several potential models and determining whether single class models 
or models with successively larger number of classes are the best fit to the data.  The initial one-
class model is similar to a standard latent growth or random effects model where all participants 
are assumed to be derived from the same population.  Various shapes were evaluated including 
linear, quadratic, and piecewise to determine which best depicted the nature of longitudinal 
change in the sample.   
With each additional model, a new class is added and evaluated using several statistical 
fit parameters to determine overall goodness of fit for each model.  The multi-class models are 
evaluated based on the fit indices (AIC, BIC, Deviance), entropy values which evaluate the 
uncertainty of classification of subjects into latent classes, and by the Lo-Mendell-Rubin test to 
evaluate if additional classes offer a significant improvement in model fit.  For AIC, BIC, and 
deviance, smaller values indicate improvement in model fit.  For entropy, values range from 0 to 
1 and larger values indicate greater certainty in classifying subjects into the latent classes.  
Classes that feature fewer than 10% of the study sample are only considered if their trajectories 
represented a meaningful difference in slope over time or if it represents a parallel class with a 
substantially higher or lower mean FCR over time (Uher et al., 2010).  Once the statistical fit 
parameters indicate that there is no improvement of fit or poorer fit with additional classes, the 
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iterative model testing is suspended.  Finally, if more than one class is detected, logistic 
regression analyses are conducted to determine which demographic, medical, and psychosocial 
characteristics predict group membership.  
Power analyses were computed for both repeated measures ANOVAs and hierarchical 
regression analyses.  Computing power analyses for repeated measures ANOVAs rather than 
growth curve models provides a more conservative standard by which to estimate the appropriate 
sample size for this study.  The first power analysis for the repeated measures ANOVAs was 
based on two repeated measures in one group where the repeated measures are assumed to have a 
small to medium correlation, r = .30.  A sample size of 125 participants with complete data 
yields power of .80 to detect an effect size = .15 at alpha = .05.  The second power analysis for 
the proposed regression analyses was based on one step containing three demographic and/or 
clinical variables followed by a second step containing the six psychosocial variables.  The first 
step is expected to account for 30% of the variance.  Therefore, a sample size of 120 participants 
with complete data yields power of .80 to detect an 8% increase in variance accounted for by the 
second step at alpha = .05.  To provide adequate power for all analyses, a target sample size of 
125 is needed.  Based on these analyses and accounting for 40% missing data due to attrition and 
random missingness, initial plans called for 175 participants to be recruited. 
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RESULTS 
 
Participants 
A total of 2,584 patients scheduled for diagnostic mammograms at Moffitt Cancer Center 
between December 2011 and January 2013 were screened for eligibility.  Of these patients, 2,092 
were ineligible (see Figure 1 on page 33).  The remaining 492 women were contacted to 
participate; of these women, 173 refused to participate, 73 could not be reached, and an 
additional 75 were ineligible before consent (e.g., indicated that they did not speak English, did 
not have Internet access, could not provide consent, cancelled the mammogram appointment, 
etc.).  Consent forms were signed by 171 women, yielding a participation rate of 51.20% among 
women eligible prior to consent.  Four were ineligible after consent (i.e., other cancer diagnoses, 
loss of internet access, or cancelled mammogram appointment), three declined, and three did not 
complete the initial (T0) survey in time, leaving 161 participants in the study sample at T0.  The 
overall participation rate for those who signed consent and completed at least one study survey 
was 48.20%.  After baseline, one participant withdrew and one patient cancelled the 
mammogram appointment.  A total of 13 patients were recalled after their mammograms for 
additional diagnostic testing to rule out a cancer recurrence and one patient was later diagnosed 
with a different primary cancer after a negative mammogram.  A total of 128 women completed 
all seven study surveys. 
Participants’ demographic and medical characteristics are shown in Table 1 (see page 
42).  They ranged in age from 33 to 86 years old (M = 61.48, SD = 9.60).  The majority of the 
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participants had completed at least some college or specialized training (84.5%), were married 
(73.3%), had a gross annual income greater than $40,000 (77.2%), and were Caucasian (93.2%).  
The sample included women diagnosed at stage 0 (16.2%), stage I (55.9%), stage II (26.7%), and 
stage IIIA (1.2%).  These women were an average of 1.74 years (SD = 0.74, range 0.49 years to 
3.86 years) since diagnosis and 1.30 years (SD = 0.69, range 0.13 years to 3.30 years) since 
treatment completion and had completed an average of 1.16 (SD = 0.90, range 0 to 4) previous 
mammograms after treatment completion.   
Participating patients (n = 161) were compared to non-responders (n = 249; i.e., those 
who were invited to participate and either declined or did not respond to the study request) on 
available demographic and clinical characteristics.  Responders were significantly more likely to 
be stage 0 (p < .01) and less likely to have received both chemotherapy and radiation treatments 
than non-responders (p = .05).  Also, responders were significantly younger (p = .03), had a 
longer time since diagnosis and treatment completion (p < .001), and had a longer duration of 
chemotherapy (p = .01).   
Descriptive Statistics 
The CBM variables were assessed only at baseline (T0).  Participants overall perceived 
mild to moderate absolute risk of breast cancer recurrence (M = 33.28, SD = 8.5), with the 
majority of responses (52.80%) rated as 1 (extremely unlikely) to 2 (somewhat unlikely).  For 
perceived relative risk of recurrence, the majority of responses (68.32%) were rated as 3 (about 
the same) when comparing one’s own risk of recurrence to that of other breast cancer patients.  
As noted above, these two risk estimates were combined on a scale that ranged from 11-60 for 
later analyses, with higher scores indicating greater perceived risk of cancer recurrence.  
Perceived severity was also moderate (M = 22.02, SD = 4.60) in this sample, as scores fell near 
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the midrange on this measure (possible range = 6 to 30).  Mean coping efficacy scores showed 
that patients believed that survivors overall believed they could cope with a cancer recurrence, 
(M = 108.09, SD = 21.49; possible range = 18 to 162).  Mean treatment efficacy scores indicated 
that participants believed that various treatments would probably or definitely provide some 
benefit if cancer returned, (M = 15.20, SD = 2.01; possible range = 5 to 20).  Mean values for 
FCR, state anxiety, and reassurance across the different measures for the pre-mammogram time 
period (T1-T3), immediate pre-post mammogram time period (T3-T4), and post-mammogram 
time period (T4-T6) are presented in Tables 2, 3, and 4 respectively (see pages 44-46).   
Evaluation of Hypothesis 1 
Growth curve modeling was conducted to test hypothesis 1 that changes in FCR would 
occur during the month leading up to the mammogram.  The following measures were assessed 
for significant change over time during the pre-mammogram time period (T1 to T3):  combined 
VAS for anxiety and worry, the CWS, and the FCRI.  For the VAS, the unconditional growth 
model showed there was no significant effect of time, linear slope = 0.01, t(158) = 0.19, p = .85. 
Further, neither linear nor quadratic time effects were observed when the quadratic term was 
added to the growth curve model (p’s < .05).  Hence, contrary to predictions, no change over 
time was observed for this measure prior to the mammogram (see Table 5 on page 47).  As 
shown in Figure 2 (see page 34), the mean VAS scores are relatively stable before the 
mammogram.  For the CWS, there was a significant effect of time in the linear growth model, 
slope = 0.01, t(158) = 2.71, p = .007, (see Table 6 on page 48),  demonstrating a gradual increase 
in CWS scores during the 30-day time period before the mammogram (see Figure 3 on page 35).  
When the quadratic term was added to the growth curve model, however, neither the linear nor 
quadratic slopes were significant (p’s > .05) and model fit was not improved (i.e., deviance for 
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the linear growth curve and for the quadratic growth curve were both 1866.8) (see Table 6).  
Hence, consistent with predictions, there was a significant linear increase in the average CWS 
score during the month before the mammogram.  For the FCRI (completed at T1 and T3 only), 
there was also a significant effect of time evaluated by repeated measures ANOVA, Wilk’s 
lambda = 0.97, F(1,150) = 4.00, p = 0.05.  Contrary to predictions, mean scores significantly 
decreased over time between a month before the mammogram and the day of the mammogram 
(see Figure 4 on page 36).   
Evaluation of Hypothesis 2 
A repeated measures ANOVA was conducted for the immediate pre-mammogram and 
immediate post-mammogram assessments (T3 to T4) for the combined VAS for anxiety and 
worry to test the hypothesis that there would be a significant decrease in FCR following receipt 
of negative mammogram results.  Consistent with predictions, there was a significant decrease 
over time for the VAS among women who were provided feedback that there were no signs of 
cancer post-mammogram, Wilk’s lambda = 0.59, F(1,139) = 97.27, p < .001 (see Figure 2).  
Evaluation of Hypothesis 3 
Growth modeling and repeated measures ANOVA were conducted to test the hypothesis 
that FCR would increase during the month following receipt of mammogram results (T4 to T6).  
FCR was evaluated during this time segment using the combined VAS measure and the CWS.  
For the VAS, the growth curve models demonstrated significant change in scores over time, with 
both linear, slope = 0.92, t(143) = 3.58, p < .001, and quadratic effects, slope = -0.02, t(143) = -
2.80, p = .006, (see Table 7 on page 49).  As shown in Figure 2, and consistent with predictions, 
mean scores increased from the low initial values following the announcement of the negative 
mammogram, with a steeper increase from T5 to T6 than from T4 to T5.  For the CWS 
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(evaluated at T5 and T6 only), there was no change over time in the mean scores from one week 
to one month post-mammogram based on repeated measures ANOVA, Wilk’s lambda = 0.99, 
F(1,135) = 1.40, p = .24 (see Figure 3). Thus, findings for the CWS were not consistent with 
predictions.  
Exploratory Analyses:  Change in State Anxiety and Reassurance over Time 
For the brief STAI, there was a significant effect of time during the pre-mammogram 
time period (T1 to T3).  Both linear, slope = 0.22, t(158) = 5.11, p < .001, and quadratic effects, 
slope = 0.005, t(158) = 3.63, p < .001, were observed (see Table 8 on page 50), indicating that 
state anxiety increased over time leading up to the mammogram, with steeper increases of mean 
anxiety scores observed immediately prior to the exam (see Figure 5 on page 37).  There was 
also a significant decrease in state anxiety over time from immediately before to immediately 
after the mammogram (T3 to T4) based on repeated measures ANOVA, Wilk’s lambda = 0.64, 
F(1,139) = 77.97, p < .001.  Examining the brief STAI scores in the post-mammogram time 
period (T4 to T6) revealed no significant linear or quadratic changes over time, p’s > .05 (see 
Table 9 on page 51).   
Finally, for the reassurance measure, the scores were significantly negatively skewed and 
kurtotic, so a square root transformation was applied before conducting growth modeling.  
During the post-mammogram time period (T4 to T6), there were significant changes in 
reassurance over time for both the first item assessing overall reassurance and for the second 
item assessing the belief that additional testing to rule out a recurrence was not necessary.  
Specifically, for the first item, there were both linear, slope = 0.03, t(143) = 4.90, p < .001, and 
quadratic effects, slope = -0.001, t(143) = -4.06, p < .001 (see Table 10 on page 52).  For the 
second item, a similar pattern emerged with linear, slope = 0.09, t(143) = 5.43, p < .001, and 
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quadratic effects over time, slope = -0.003, t(143) = -4.66, p < .001 (see Table 11 on page 53).  
Mean scores for both items show a gradual decline in reassurance over time, with a steeper 
decline within the first week after the mammogram (T4 to T5) than in the weeks after the 
mammogram (T5 to T6) (see Figure 6 on page 38). 
Evaluation of Hypothesis 4 
The next set of hypotheses (i.e., 4, 5, and 6) examine whether CBM variables are able to 
predict the observed changes in FCR across each time segment after controlling for clinical and 
demographic characteristics.  To examine which variables predict increases in FCR during the 
pre-mammogram time segment (T1 to T3) (Hypothesis 4), univariate analyses were first 
conducted to determine which demographic, clinical, and CBM variables measured at T0 were 
correlated with the various measures of FCR at each pre-mammogram time point (see Tables 12-
14 on pages 54-56).  Because there were significant correlations between one or more FCR 
measures from T1 to T3 (pre-mammogram time points) and age, income, and education, these 
variables were included as predictors in the subsequent hierarchical multiple regressions.  As for 
clinical variables, none were significantly related to FCR at any time point and so none were 
included in the subsequent analyses.  Finally, the CBM variables of risk, severity, coping self-
efficacy, and reassurance-seeking behaviors were significantly related to all FCR measures at all 
time points and so all were included in the hierarchical regression analyses.  There were no 
significant correlations between FCR and treatment efficacy beliefs across all measures and all 
time points; hence, it will not be included in the subsequent analyses. 
For hierarchical regression analyses, the score on the FCR measure at the final time point 
in the segment served as the dependent variable.  The initial score on the FCR measure was 
entered in the first step to create a residualized change score, followed by relevant demographic 
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variables.  The relevant CBM variables were then entered on the final step to determine if they 
accounted for additional variance in the FCR score at the final time point in the segment.  Only 
FCR measures that demonstrated significant change over time were evaluated (i.e., the CWS and 
the FCRI).   
For the CWS (see Table 15 on page 57), the initial score accounted for 53% of the 
variance in scores at T3 on the first step, F(1,123) = 136.14, p < .001.  Inclusion of the 
demographic variables on the second step did not explain additional variance, F(3,120) = 0.69, p 
= .56.  On the final step, an additional 4% of the variance was explained by the CBM variables 
entered as a group, F(4,116) = 2.82, p = .03.  No single CBM variable was found to be a 
significant predictor controlling for all other CBM variables.  In follow-up analyses, each CBM 
variable was entered on its own on the third step to determine if any separately made a 
significant contribution to the variance accounted for. Neither risk nor coping self-efficacy 
contributed significant variance accounted for when added to the model individually (see Table 
16 on page 58).  However, greater perceived severity of the consequences of a recurrence 
contributed 3% additional unique variance, F(1,119) = 6.09, p = .01, and reassurance-seeking 
behaviors contributed 2% additional variance, F(1,119) = 4.31, p = .04, when entered 
individually.  
For FCRI scores, initial FCRI scores entered on the first step accounted for 73% unique 
variance in FCRI scores at T3, F(1,122) = 323.54, p < .001.  Demographic variables on the 
second step accounted for 2% additional variance accounted for, F(3,123) = 3.13, p = .03, with 
lower education significantly predicting higher scores at T3.  When CBM variables were added 
as a block on the final step, an additional 2% unique variance was accounted for, F(4,115) = 
3.19, p = .02, with lower coping self-efficacy to handle a cancer recurrence significantly related 
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to higher FCRI scores at T3 (see Table 17 on page 59).  Again, CBM variables were also entered 
on their own on the final step in additional hierarchical multiple regression analyses.  The pattern 
of results did not change (see Table 18 on page 60).  Only coping self-efficacy contributed 
significant unique variable above initial FCRI scores and demographic variables, F(1,118) = 
12.05, p < .001. 
Evaluation of Hypothesis 5 
Hypothesis 5 examined whether CBM variables would account for additional variance in 
the decline of FCR between the immediate pre-mammogram and immediate post-mammogram 
time segment after controlling for relevant clinical and demographic characteristics.  Similar to 
hypothesis 4, predictors of FCR were selected by examining which clinical, demographic, and 
CBM variables were correlated with FCR at either time point (see Table 14).  Next, a 
hierarchical multiple regression analysis predicting FCR at T4 was conducted with FCR at T3 
entered on the first step, relevant clinical and demographic variables on the second step, and 
finally CBM variables on the third step. 
The following variables were identified as significant correlates of FCR during the 
immediate pre-mammogram to immediate post-mammogram time segment (T3 to T4) and were 
therefore used to predict change in FCR between T3 and T4:  age, income, education, risk, 
severity, coping self-efficacy, and reassurance-seeking behaviors.  For the combined VAS 
measure, the initial score at T3 accounted for 42% of the variance in scores at T4, F(1,114) = 
81.79, p < .001.  The addition of the demographic variables on the second step did not contribute 
additional variance, F(3,111) = 1.89, p = .14.  Finally, the addition of the CBM variables as a 
group on the third step also did not contribute a significant proportion of the variance, F(4,107) = 
0.15, p = .96, and none of these variables were significant predictors of VAS scores (see Table 
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19 on page 61).  When entered separately on the final step, no CBM variable accounted for 
additional significant variance in VAS scores at T4 (see Table 20 on page 62). 
Evaluation of Hypothesis 6 
Next, predictors of change in FCR during the post-mammogram time segment (T4 to T6) 
were evaluated.  It was hypothesized that the CBM variables would account for additional 
variance in the increase of FCR during the month following the mammogram after controlling 
for relevant clinical and demographic characteristics.  Similar to hypotheses 4 and 5, predictors 
of FCR were selected by examining univariate relationships between FCR across the post-
mammogram time points and clinical, demographic, and CBM variables (see Table 14).  Then, 
the hierarchical multiple regression analysis was conducted to predict FCR at T6 with FCR at T4 
on the first step, relevant clinical and demographic variables on the second step, and the CBM 
variables on the third step. 
For the post-mammogram time segment (T4 to T6), the following variables were 
identified as significant correlates of FCR and therefore were used to predict change in FCR 
between T4 and T6:  income, education, risk, severity, coping self-efficacy, and reassurance-
seeking behaviors.  Examining the combined VAS scores at T6, a significant proportion of the 
variance (29%) was accounted for by the initial VAS scores, F(1,116) = 47.15, p < .001. After 
the demographic variables were entered on the second step, an additional 5% unique variance 
was accounted for, F(2,114) = 5.86, p = .004, with lower income significantly predicting lower 
VAS scores at T6.  With the addition of the CBM variables as a group on the third step, there 
was no significant increase in variance accounted for, F(4,110) = 0.98, p = .42 (see Table 21 on 
page 63).  When each CBM variable was entered on its own on the final step, again, none were 
found to contribute significant unique variance (see Table 22 on page 64). 
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Exploratory Growth Mixture Models  
The final set of analyses explored the use of growth mixture models to detect overall 
patterns of change in FCR over time.  Per the analysis plan, a one-class latent growth curve 
model was first fit to the data over the entire course of the study (T1 to T6).  For the piecewise 
models, each of the following was evaluated:  1) a linear piecewise model with linear slopes for 
the pre-mammogram (T1 to T3) and post-mammogram (T4 to T6) segments; and 2) a combined 
linear and quadratic piecewise model with a linear slope for the pre-mammogram and a quadratic 
slope for the post-mammogram segment. 
Based on the fit indices presented in Table 23 (see page 65), the piecewise growth model 
with a linear pre-mammogram segment and quadratic post-mammogram segment was 
determined to best fit the data.  The residual variances were constrained to be equal over time 
and the variance of the linear slope from T1 to T3 was constrained to 0, which reflected the lack 
of significant findings for systematic change over time observed for the combined VAS measure.  
The quadratic slope during the post-mammogram time segment (T4 to T6) was not constrained 
to allow for variability in the change over time for this piece.  This model was used as the basis 
for the addition of latent classes for the growth mixture models (see Figure 7 on page 39).   
Successive models were fit to the data with additional latent classes examined one at a 
time until there was no longer an improvement in fit.  The 2-class model demonstrated an 
improvement in model fit according to the fit indices and significant improvement over the 1-
class model according to the Lo-Mendell-Rubin test, p < .001 (see Table 24 on page 66).  The 
first class included 75.5% of study subjects and the second class included 24.5% (see Figure 8 on 
page 40).  There was very little overlap between the probabilities that each individual belonged 
to one class over the other.  For the first class, the average probability that a member belonged to 
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this class was 0.970 and the probability that the member did not belong to this class was 0.030.  
For the second class, the average probability that a member belonged to this class was 0.996 and 
the probability that the member did not belong was 0.004.   
The 3-class model also demonstrated an improvement in fit indices and had a statistically 
better fit to the data than the previous 2-class model according to the Lo-Mendell-Rubin test, p = 
.05 (see Table 24).  The three classes accounted for 74.4%, 19.3%, and 6.3% of the study sample 
for each class (see Figure 9 on page 41).  There was also good agreement between which class 
members belonged to in this model.  For the first class, the average probability that a member 
belonged was 0.996; the probability that the member belonged to the second class was 0.004, and 
the probability that the member belonged to the third class was 0.000.  For the second class, the 
average probability that a member belonged to this class was 0.979, and was 0.018 and 0.003 for 
the first and third classes respectively.  Finally, the average probability that a member belonged 
to the third class was 0.993; the probability that the member belonged to the first class was 
0.000, and probability of membership in the second class was 0.007.  However, the smallest class 
in the 3-class model is less than 10% of the study sample and represents a subgroup with a 
marginally different trajectory from what is represented by the 2-class model.  Therefore, it is 
unlikely that this additional class represents a subgroup of patients with clinically significant 
differences in their FCR trajectories or overall levels of FCR before and after mammograms. 
Finally, a 4-class model was tested to determine if additional classes would provide 
improvement in model fit.  The estimation of this model was unstable, however, as the best log 
likelihood value was not replicated even with 1000 random starts of 10 iterations so the estimates 
provided should be interpreted with caution.  The fit indices revealed that the model fit was 
somewhat improved over the previous model, with lower values for deviance, AIC, and BIC.  
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However, entropy did not improve from the previous model and examination of the Lo-Mendell-
Rubin test revealed no significant improvement over the previous model, p = .07.  This model 
also suffered from the problem of containing at least one class with fewer than 10% of the study 
sample and neither the trajectory nor mean FCR across time points was meaningfully different 
from the other classes produced in the models with fewer classes.  Hence, no further iterations of 
multi-class models were estimated.   
Based on all of the information after several iterations of multi-class models, it can be 
concluded that the 2-class model provides the most parsimonious and statistically satisfactory fit 
of the data from this sample. 
Predicting class membership.  Per the analysis plan, logistic regression analyses were 
conducted to determine whether demographic, clinical, or CBM variables predicted which 
patients belonged to each class identified in the model.  No demographic or clinical 
characteristics were significant predictors of class membership in the univariate logistic 
regressions (see Table 25 on page 67).  However, several CBM variables, including risk, 
severity, coping self-efficacy beliefs, and reassurance-seeking behaviors, were significant 
predictors.  The significant predictors from the univariate analyses were used in multivariate 
logistic regression analyses to determine if each predicted class membership when controlling for 
the other CBM variables.  The multivariate analyses revealed that risk, coping self-efficacy, and 
reassurance-seeking behaviors each significantly predicted class membership (see Table 26 on 
page 69).  Findings indicated that those who reported greater perceived risk, lower coping self-
efficacy, and greater reassurance-seeking behaviors were more likely to belong to the high-FCR 
class than to the low-FCR class.  
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Figure 1.  Response rate throughout recruitment and surveying process. 
2584 screened for 
eligibility 
492 eligible to be 
contacted 
419 reached 
173 refused 
2092 ineligible 
73 unreachable 
75 ineligible 
before consent 
171 consented 
4 ineligible after 
consent 
157 completed T1 
 
161 completed T0 
13 recalled for 
additional 
diagnostic 
testing 
 
156 completed T2 
 
156 completed T3 
 
143 completed T4 
 
139 completed T5 
 
142 completed T6 
 
3 declined after 
consent 
1 declined 
1 recurred 
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Figure 2.  Mean worry and anxiety VAS scores across all study time points. VAS = Visual 
Analogue Scale. 
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Figure 3.  Mean Cancer Worry Scale scores across all study time points. CWS = Cancer Worry 
Scale. 
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Figure 4.  Mean Fear of Cancer Recurrence Inventory scores across all study time points. FCRI 
= Fear of Cancer Recurrence Inventory. 
 
 
 
 
 
 
 
 37 
 
 
Figure 5.  Mean State Anxiety scores across all study time points. STAI = Brief State Trait 
Anxiety Inventory.  
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Figure 6.  Mean Reassurance Scale scores across all study time points. 
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Figure 7. Latent growth curve model of worry and anxiety VAS over time 
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Figure 8. 2-class growth mixture model of worry and anxiety VAS over time 
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Figure 9. 3-class growth mixture model of worry and anxiety VAS over time
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Table 1. Sample characteristics 
 n % 
Race   
     Caucasian    150 93.17 
     African American        3 1.86 
     Asian        6 3.73 
     Other        2 1.24 
Ethnicity   
     Hispanic    8 4.97 
     Non-Hispanic    153 95.03 
Marital Status   
     Single    7 4.35 
     Married    118 73.29 
     Separated    2 1.24 
     Divorced 17 10.56 
     Widowed 17 10.56 
Annual Income   
     < $40,000  37 22.98 
     > $40,000     96 59.63 
     Prefer not to respond     28 17.39 
Education   
     Less than high school   3 1.86 
     High school 22 13.66 
     Some college 48 29.81 
     College graduate 54 33.54 
     Graduate degree 34 21.12 
Stage at diagnosis   
     Stage 0  26 16.15 
     Stage I  90 55.90 
     Stage II  43 26.71 
     Stage IIIA    2 1.24 
Surgery Type   
     Lumpectomy    121 75.16 
     Bilateral Lumpectomies    1 0.62 
     Mastectomy  36 22.36 
     Lumpectomy & Mastectomy    3 1.86 
Treatment   
     Surgery & Radiation  93 57.76 
     Surgery & Chemotherapy    9 5.59 
     Surgery, Chemotherapy, & Radiation  34 21.12 
     Surgery Only  23 14.29 
Adjuvant Hormone Therapy   
     Yes    127 78.88 
     No  32 19.88 
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Table 1(Continued) 
 n % 
Previous Post-Treatment Mammograms   
     None   41 25.47 
     1  65 40.37 
     2  46 28.57 
     3    7 4.35 
     4    2 1.24 
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Table 2. Fear of cancer recurrence and state anxiety pre-mammogram 
 
  
M (SD) 
 
  
Time 1 
 
 
Time 2 
 
Time 3 
 
FCRI 
 
58.47 (22.76) 
n = 156 
 
_ 
 
 
56.74 (26.07) 
n = 155 
 
CWS 
 
5.92 (2.35) 
n = 157 
 
6.20 (2.30) 
n = 156 
 
6.32 (2.58) 
n = 155 
 
Anxiety VAS 
 
33.77 (26.23) 
n = 157 
 
34.37 (26.82) 
n = 155 
 
35.12 (29.78) 
n = 156 
 
Worry VAS 
 
36.81 (26.60) 
n = 157 
 
37.17 (26.10) 
n = 155 
 
36.87 (28.85) 
n = 156 
 
Combined VAS 
 
35.29 (25.90) 
n = 157 
 
35.77 (25.88) 
n = 155 
 
35.99 (28.67) 
n = 156 
 
STAI 
 
9.71 (3.53) 
n = 157 
 
10.63 (4.07) 
n = 156 
 
12.21 (4.38) 
n = 156 
 
Note.  FCRI = Fear of Cancer Recurrence Inventory; CWS = Cancer Worry Scale; VAS = Visual 
Analogue Scale; STAI = Brief State Trait Anxiety Inventory. 
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Table 3. Fear of cancer recurrence and state anxiety immediately pre- and immediately post-
mammogram 
  
M (SD) 
 
  
Time 3 
 
 
Time 4 
 
Anxiety VAS 
 
35.12 (29.78) 
n = 156 
 
16.57 (19.61) 
n = 143 
 
Worry VAS 
 
36.87 (28.85) 
n = 156 
 
17.52 (19.44) 
n = 143 
 
Combined VAS 
 
35.99 (28.67) 
n = 156 
 
17.04 (18.77) 
n = 143 
 
STAI 
 
12.21 (4.38) 
n = 156 
 
8.94 (3.05) 
n = 143 
 
Note.  VAS = Visual Analogue Scale; STAI = Brief State Trait Anxiety Inventory. 
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Table 4. Fear of cancer recurrence, state anxiety, and reassurance post-mammogram 
 
  
M (SD) 
 
  
Time 4 
 
 
Time 5 
 
Time 6 
 
FCRI 
 
_ 
 
 
_ 
 
 
50.43 (24.52) 
n = 142 
 
CWS 
 
_ 
 
 
5.48 (1.87) 
n = 139 
 
5.32 (2.01) 
n = 142 
 
Anxiety VAS 
 
16.57 (19.61) 
n = 143 
 
19.85 (21.50) 
n = 139 
 
23.04 (21.54) 
n = 142 
 
Worry VAS 
 
17.52 (19.44) 
n = 143 
 
22.94 (22.28) 
n = 139 
 
25.92 (23.02) 
n = 142 
 
Combined VAS 
 
17.04 (18.77) 
n = 143 
 
21.40 (21.55) 
n = 139 
 
24.48 (21.59) 
n = 142 
 
STAI 
 
8.94 (3.05) 
n = 143 
 
9.29 (3.29) 
n = 139 
 
9.32 (3.41) 
n = 142 
 
Reassurance #1 
 
 
9.29 (1.22) 
n = 143 
 
8.80 (1.47) 
n = 139 
 
8.58 (1.71) 
n = 142 
 
Reassurance #2 
 
 
8.90 (2.13) 
n = 143 
 
7.60 (3.06) 
n = 139 
 
7.46 (3.07) 
n = 142 
 
Note.  FCRI = Fear of Cancer Recurrence Inventory; CWS = Cancer Worry Scale; VAS = Visual 
Analogue Scale; STAI = Brief State Trait Anxiety Inventory. 
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Table 5. Unconditional growth curve models examining the effect of time on worry and anxiety VAS scores before the mammogram 
  
Fully Unconditional Model 
 
  
Linear Growth Model 
  
Quadratic Growth Model 
 
Fixed Effects 
 
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
 
   Intercept 
 
35.63 
 
1.89 
 
18.81 
 
<.001 
  
35.75 
 
2.07 
 
17.24 
 
<.001 
  
35.44 
 
2.17 
 
16.33 
 
<.001 
 
   Linear Slope 
      
0.01 
 
0.05 
 
0.19 
 
.85 
  
-0.11 
 
0.25 
 
-0.44 
 
.66 
 
   Quadratic Slope 
           
-0.00 
 
0.01 
 
-0.49 
 
.62 
 
Random Effects 
 
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
 
   Intercept 
 
498.42 
 
64.45 
 
7.73 
 
<.001 
  
538.20 
 
76.50 
 
7.04 
 
<.001 
  
538.16 
 
76.46 
 
7.04 
 
<.001 
 
   Time 
      
0.00 
 
0.01 
 
0.60 
 
.27 
  
0.00 
 
0.01 
 
0.59 
 
.28 
 
   Residual 
 
218.66 
 
17.62 
 
12.41 
 
<.001 
  
217.59 
 
17.53 
 
12.41 
 
<.001 
  
217.33 
 
17.51 
 
12.41 
 
<.001 
 
Model Fit 
 
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
4174.6 
 
2 
 
4180.6 
 
4194.1 
  
4173.1 
 
4 
 
4183.1 
 
4198.5 
  
4172.9 
 
4 
 
4184.9 
 
4203.3 
 
Note.  AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; Coef. = Coefficient Estimate; Dev. = Deviance; 
Param. = Number of Parameters; VAS = Visual Analogue Scale.  
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Table 6. Unconditional growth curve models examining the effect of time on Cancer Worry Scale scores before the mammogram 
  
Fully Unconditional Model 
 
  
Linear Growth Model 
  
Quadratic Growth Model 
 
Fixed Effects 
 
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
 
   Intercept 
 
6.15 
 
0.17 
 
35.33 
 
<.001 
  
6.30 
 
0.19 
 
33.63 
 
<.001 
  
6.30 
 
0.19 
 
32.38 
 
<.001 
 
   Linear Slope 
      
0.01 
 
0.00 
 
2.71 
 
.01 
  
0.01 
 
0.02 
 
0.53 
 
.60 
 
   Quadratic Slope 
           
-0.00 
 
0.00 
 
-0.06 
 
.96 
 
Random Effects 
 
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
 
   Intercept 
 
4.33 
 
0.54 
 
7.96 
 
<.001 
  
4.67 
 
0.63 
 
7.38 
 
<.001 
  
4.67 
 
0.63 
 
7.38 
 
<.001 
 
   Time 
      
0.00 
 
0.00 
 
0.81 
 
.21 
  
0.00 
 
0.00 
 
0.81 
 
.21 
 
   Residual 
 
1.50 
 
0.12 
 
12.41 
 
<.001 
  
1.37 
 
0.16 
 
8.78 
 
<.001 
  
1.37 
 
17.51 
 
8.77 
 
<.001 
 
Model Fit 
 
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
1876.3 
 
2 
 
1882.3 
 
1895.8 
  
1866.8 
 
4 
 
1878.8 
 
1897.3 
  
1866.8 
 
4 
 
1880.8 
 
1902.4 
 
Note.  AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; Coef. = Coefficient Estimate; Dev. = Deviance; 
Param. = Number of Parameters.  
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Table 7. Unconditional growth curve models examining the effect of time on worry and anxiety VAS scores after the mammogram 
  
Fully Unconditional Model 
 
  
Linear Growth Model 
  
Quadratic Growth Model 
 
Fixed Effects 
 
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
 
   Intercept 
 
21.12 
 
1.49 
 
14.13 
 
<.001 
  
18.65 
 
1.59 
 
11.71 
 
<.001 
  
17.21 
 
1.67 
 
10.28 
 
<.001 
 
   Linear Slope 
      
0.22 
 
0.06 
 
3.94 
 
<.001 
  
0.92 
 
0.26 
 
3.58 
 
<.001 
 
   Quadratic Slope 
           
-0.02 
 
0.01 
 
-2.80 
 
.01 
 
Random Effects 
 
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
 
   Intercept 
 
265.24 
 
38.35 
 
6.92 
 
<.001 
  
294.63 
 
44.11 
 
6.68 
 
<.001 
  
297.26 
 
43.97 
 
6.76 
 
<.001 
 
   Time 
      
0.19 
 
0.06 
 
3.12 
 
<.001 
  
0.19 
 
0.06 
 
3.25 
 
<.001 
 
   Residual 
 
168.75 
 
14.28 
 
11.81 
 
<.001 
  
113.29 
 
13.92 
 
8.13 
 
<.001 
  
108.56 
 
13.35 
 
8.13 
 
<.001 
 
Model Fit 
 
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
3626.8 
 
2 
 
3632.8 
 
3646.3 
  
3597.2 
 
4 
 
3609.2 
 
3627.6 
  
3589.5 
 
4 
 
3603.5 
 
3625.0 
 
Note.  AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; Coef. = Coefficient Estimate; Dev. = Deviance; 
Param. = Number of Parameters; VAS = Visual Analogue Scale. 
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Table 8. Unconditional growth curve models examining the effect of time on State Anxiety scores before the mammogram 
  
Fully Unconditional Model 
 
  
Linear Growth Model 
  
Quadratic Growth Model 
 
Fixed Effects 
 
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
 
   Intercept 
 
10.83 
 
0.27 
 
40.30 
 
<.001 
  
11.71 
 
0.32 
 
37.11 
 
<.001 
  
12.12 
 
0.33 
 
36.31 
 
<.001 
 
   Linear Slope 
      
0.07 
 
0.01 
 
7.21 
 
<.001 
  
0.22 
 
0.04 
 
5.11 
 
<.001 
 
   Quadratic Slope 
           
0.00 
 
0.00 
 
3.63 
 
<.001 
 
Random Effects 
 
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
 
   Intercept 
 
8.70 
 
1.31 
 
6.65 
 
<.001 
  
11.20 
 
1.78 
 
6.30 
 
<.001 
  
11.26 
 
1.76 
 
6.38 
 
<.001 
 
   Time 
      
0.00 
 
0.00 
 
1.26 
 
.10 
  
0.00 
 
0.00 
 
1.30 
 
.10 
 
   Residual 
 
8.27 
 
0.67 
 
12.44 
 
<.001 
  
6.90 
 
0.55 
 
12.44 
 
<.001 
  
6.64 
 
0.53 
 
12.44 
 
<.001 
 
Model Fit 
 
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
2546.6 
 
2 
 
2552.6 
 
2566.1 
  
2490.5 
 
4 
 
2500.5 
 
2515.8 
  
2477.6 
 
4 
 
2489.6 
 
2508.0 
 
Note.  AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; Coef. = Coefficient Estimate; Dev. = Deviance; 
Param. = Number of Parameters. 
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Table 9. Unconditional growth curve models examining the effect of time on State Anxiety scores after the mammogram 
  
Fully Unconditional Model 
 
  
Linear Growth Model 
  
Quadratic Growth Model 
 
Fixed Effects 
 
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
 
   Intercept 
 
9.17 
 
0.22 
 
42.18 
 
<.001 
  
9.05 
 
0.24 
 
37.81 
 
<.001 
  
8.92 
 
0.26 
 
34.45 
 
<.001 
 
   Linear Slope 
      
0.01 
 
0.01 
 
1.06 
 
.29 
  
0.07 
 
0.05 
 
1.45 
 
.15 
 
   Quadratic Slope 
           
-0.00 
 
0.00 
 
-1.25 
 
.21 
 
Random Effects 
 
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
 
   Intercept 
 
4.91 
 
0.81 
 
6.00 
 
<.001 
  
5.67 
 
1.03 
 
5.49 
 
<.001 
  
5.71 
 
1.03 
 
5.53 
 
<.001 
 
   Time 
      
0.00 
 
0.00 
 
3.00 
 
.001 
  
0.01 
 
0.00 
 
3.09 
 
.001 
 
   Residual 
 
5.61 
 
0.47 
 
11.83 
 
<.001 
  
4.09 
 
0.50 
 
8.21 
 
<.001 
  
4.03 
 
0.49 
 
8.20 
 
<.001 
 
Model Fit 
 
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
2118.4 
 
2 
 
2124.4 
 
2137.9 
  
2106.0 
 
4 
 
2118.0 
 
2136.4 
  
2104.5 
 
4 
 
2118.5 
 
2139.9 
 
Note.  AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; Coef. = Coefficient Estimate; Dev. = Deviance; 
Param. = Number of Parameters.  
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Table 10. Unconditional growth curve models examining the effect of time on Reassurance Scale scores (item 1) after the 
mammogram 
  
Fully Unconditional Model 
 
  
Linear Growth Model 
  
Quadratic Growth Model 
 
Fixed Effects 
 
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
 
   Intercept 
 
1.38 
 
0.03 
 
42.79 
 
<.001 
  
1.31 
 
0.03 
 
42.54 
 
<.001 
  
1.26 
 
0.03 
 
37.54 
 
<.001 
 
   Linear Slope 
      
0.01 
 
0.00 
 
5.13 
 
<.001 
  
0.03 
 
0.01 
 
4.90 
 
<.001 
 
   Quadratic Slope 
           
-0.00 
 
0.00 
 
-4.06 
 
<.001 
 
Random Effects 
 
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
 
   Intercept 
 
0.12 
 
0.02 
 
6.54 
 
<.001 
  
0.09 
 
0.02 
 
5.36 
 
<.001 
  
0.09 
 
0.02 
 
5.48 
 
<.001 
 
   Time 
      
0.00 
 
0.00 
 
1.89 
 
.03 
  
0.00 
 
0.00 
 
1.97 
 
.02 
 
   Residual 
 
0.09 
 
0.01 
 
11.77 
 
<.001 
  
0.08 
 
0.01 
 
11.80 
 
<.001 
  
0.08 
 
0.01 
 
11.80 
 
<.001 
 
Model Fit 
 
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
425.0 
 
2 
 
431.0 
 
444.5 
  
383.7 
 
4 
 
393.7 
 
409.0 
  
367.7 
 
4 
 
379.7 
 
398.1 
 
Note.  AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; Coef. = Coefficient Estimate; Dev. = Deviance; 
Param. = Number of Parameters.  
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Table 11. Unconditional growth curve models examining the effect of time on Reassurance Scale scores (item 2) after the 
mammogram 
  
Fully Unconditional Model 
 
  
Linear Growth Model 
  
Quadratic Growth Model 
 
Fixed Effects 
 
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
  
Coef. 
 
SE 
 
T-ratio 
 
p 
 
   Intercept 
 
0.93 
 
0.07 
 
12.88 
 
<.001 
  
0.76 
 
0.07 
 
10.42 
 
<.001 
  
0.60 
 
0.08 
 
7.52 
 
<.001 
 
   Linear Slope 
      
0.01 
 
0.00 
 
4.85 
 
<.001 
  
0.09 
 
0.02 
 
5.43 
 
<.001 
 
   Quadratic Slope 
           
-0.00 
 
0.00 
 
-4.66 
 
<.001 
 
Random Effects 
 
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
  
Est. 
 
SE 
 
Z-value 
 
p 
 
   Intercept 
 
0.55 
 
0.09 
 
6.07 
 
<.001 
  
0.43 
 
0.09 
 
4.93 
 
<.001 
  
0.46 
 
0.10 
 
4.67 
 
<.001 
 
   Time 
      
0.00 
 
0.00 
 
1.26 
 
.10 
  
0.00 
 
0.00 
 
0.66 
 
.26 
 
   Residual 
 
0.60 
 
0.05 
 
11.83 
 
<.001 
  
0.54 
 
0.05 
 
11.83 
 
<.001 
  
0.48 
 
0.06 
 
8.11 
 
<.001 
 
Model Fit 
 
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
Dev. 
 
Param. 
 
AIC 
 
BIC 
  
1173.9 
 
2 
 
1179.9 
 
1193.4 
  
1144.4 
 
4 
 
1154.4 
 
1169.8 
  
1124.2 
 
4 
 
1138.2 
 
1159.7 
 
Note.  AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; Coef. = Coefficient Estimate; Dev. = Deviance; 
Param. = Number of Parameters.  
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Table 12. Correlations of clinical, demographic, and Cognitive-Behavioral Model variables and 
Cancer Worry Scale across all study time points 
 
 
 
  T1 
 
 
  T2 
 
  T3 
 
  T4 
 
  T6 
Clinical Characteristics      
Stage .12 .10 .03 .02 .05 
Time since Diagnosis .06 .09 .02 .12 .07 
Time since Treatment .05 .10 .05 .09 .04 
Mastectomy (yes or no) -.03 -.12 -.12 .01 .01 
Chemotherapy (yes or no) .02 .02 -.05 .02 -.01 
Radiation (yes or no) .05 .07 .05 .12 .01 
Chemotherapy + Radiation     
(yes or no) 
.04 .07 -.02 .06 -.02 
Hormone Therapy (yes or no) .02 .00 .02 .12 .00 
Family History of Breast 
Cancer (yes or no) 
.05 .07 .06 .00 .08 
Number of Previous 
Mammograms 
.11 .14 .12 .09 .03 
Demographic Characteristics      
Age -.15 -.11 -.16 -.08 .01 
Race (white or not) .10 -.05 .02 -.09 .03 
$40K Income (yes or no) -.36*** -.29*** -.33*** -.31*** -.28** 
College Education (yes or no) -.34*** -.26** -.26*** -.29*** -.21* 
Marital Status (married or not) -.06 -.07 -.15 .05 .11 
Menopausal Status -.07 .01 -.07 -.06 .05 
CBM Variables      
Perceived Risk .32*** .28*** .31*** .16 .21* 
Perceived Severity .40*** .37*** .42*** .37*** .31*** 
Coping Self-Efficacy Beliefs -.48*** -.47*** -.41*** -.39*** -.38*** 
Treatment Efficacy Beliefs -.08 .00 -.07 -.05 -.02 
Reassurance-Seeking Behaviors .25** .24** .31*** .33*** .29*** 
Note.  CBM = Cognitive-Behavioral Model. 
*p < .05. **p < .01. ***p < .001. 
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Table 13. Correlations of clinical, demographic, and Cognitive-Behavioral Model variables and 
Fear of Cancer Recurrence Inventory across all study time points 
 
 
 
  T1 
 
 
  T3 
 
  T6 
Clinical Characteristics    
Stage .12 .12 .09 
Time since Diagnosis .14 .10 .10 
Time since Treatment .10 .07 .04 
Mastectomy (yes or no) -.04 -.07 -.10 
Chemotherapy (yes or no) .08 .06 .13 
Radiation (yes or no) .06 .05 .13 
Chemotherapy + Radiation     
(yes or no) 
.11 .08 .14 
Hormone Therapy (yes or no) .03 .07 .04 
Family History of Breast 
Cancer (yes or no) 
.07 .01 .05 
Number of Previous 
Mammograms 
.12 .09 .08 
Demographic Characteristics    
Age -.16* -.19* -.15 
Race (white or not) .06 .07 -.03 
$40K Income (yes or no) -.27** -.35*** -.25** 
College Education (yes or no) -.27*** -.35*** -.26** 
Marital Status (married or not) -.02 -.02 .06 
Menopausal Status -.09 -.04 -.04 
CBM Variables    
Perceived Risk .36*** .31*** .29*** 
Perceived Severity .51*** .48*** .52*** 
Coping Self-Efficacy Beliefs -.41*** -.48*** -.47*** 
Treatment Efficacy Beliefs -.02 -.06 .00 
Reassurance-Seeking Behaviors .39*** .31*** .36*** 
Note.  CBM = Cognitive-Behavioral Model. 
*p < .05. **p < .01. ***p < .001. 
 
 
 
 
 
 
 56 
 
Table 14. Correlations of clinical, demographic, and Cognitive-Behavioral Model variables and 
worry and anxiety VAS across all study time points 
 
 
 
  T1 
 
 
  T2 
 
  T3 
 
  T4 
 
  T5 
 
  T6 
 
Clinical Characteristics 
      
Stage .08 .01 .05 -.04 .02 -.03 
Time since Diagnosis .05 .10 .01 .03 .02 .07 
Time since Treatment .05 .10 .01 .03 .05 .09 
Mastectomy (yes or no) -.03 -.08 -.14 .03 .07 .03 
Chemotherapy (yes or no) .09 .10 .03 .08 .05 .04 
Radiation (yes or no) .04 .06 .06 -.01 .03 .00 
Chemotherapy + Radiation     
(yes or no) 
.09 .09 .05 .05 .09 .03 
Hormone Therapy (yes or no) -.02 .02 .01 -.04 .05 .05 
Family History of Breast 
Cancer (yes or no) 
.14 .03 .01 -.04 -.04 -.13 
Number of Previous 
Mammograms 
.03 .04 .02 .02 -.02 .06 
Demographic Characteristics       
Age -.18* -.09 -.22** -.04 .02 .00 
Race (white or not) .04 -.07 .04 .03 -.08 -.13 
$40K Income (yes or no) -.23** -.14 -.31*** -.21* -.23* -.23* 
College Education (yes or no) -.22** -.18* -.29*** -.29*** -.21* -.16 
Marital Status (married or not) -.20* -.11 -.12 .06 -.03 -.02 
Menopausal Status -.11 -.03 -.14 -.06 -.03 -.04 
CBM Variables       
Perceived Risk .46*** .31*** .38*** .34*** .26*** .24** 
Perceived Severity .37*** .30*** .41*** .22** .19* .21* 
Coping Self-Efficacy Beliefs -.43*** -.31*** -.42*** -.33*** -.33*** -.32*** 
Treatment Efficacy Beliefs -.11 -.03 -.09 -.08 -.09 -.05 
Reassurance-Seeking Behaviors .21** .21** .20** .15 .20** .19* 
Note.  CBM = Cognitive-Behavioral Model; VAS = Visual Analogue Scale. 
*p < .05. **p < .01. ***p < .001. 
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Table 15. Hierarchical regression analysis predicting Cancer Worry Scale scores at time 3 from 
demographic and Cognitive-Behavioral Model variables 
 
Predictor 
 
β 
 
 
R
2 
 
 
ΔR2 
 
 
ΔF 
 
Step 1:  Initial Score 
 
  
.53 
  
136.14*** 
     T1 CWS .59***    
Step 2:  Demographic Variables  .53 .00 0.69 
     Age -.02    
     Income -.06    
     Education .05    
Step 3:  CBM Variables  .57 .04 2.82* 
     Risk .01    
     Severity .11    
     Coping Self-Efficacy -.10    
     Reassurance-Seeking Behaviors .13
†
    
Note.  N = 125. CBM = Cognitive-Behavioral Model; CWS = Modified Cancer Worry Scale. 
†
 p < .10. *p < .05. **p < .01. ***p < .001. 
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Table 16. Hierarchical regression analyses predicting Cancer Worry Scale scores at time 3 from 
demographic and Cognitive-Behavioral Model variables entered individually on the 3
rd
 step 
 
Predictor 
 
β 
 
 
R
2 
 
 
ΔR2 
 
 
ΔF 
 
Step 1:  Initial Score 
 
 .53  136.14*** 
     T1 CWS .70***    
Step 2:  Demographic Variables  .53 .00 0.69 
     Age -.04    
     Income -.07    
     Education .07    
Step 3:  CBM Variables     
     Risk .04 .53 .00  0.28 
     Severity .18** .56 .03 6.90** 
     Coping Self-Efficacy -.11 .54 .01 2.51 
     Reassurance-Seeking Behaviors .13* .55 .02 4.31* 
Note.  N = 125. CBM = Cognitive-Behavioral Model; CWS = Modified Cancer Worry Scale. 
*p < .05. **p < .01. ***p < .001. 
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Table 17. Hierarchical regression analysis predicting Fear of Cancer Recurrence Inventory 
scores at time 3 from demographic and Cognitive-Behavioral Model variables 
 
Predictor 
 
β 
 
 
R
2 
 
 
ΔR2 
 
 
ΔF 
 
Step 1:  Initial Score 
 
  
.73 
  
323.54*** 
     T1 FCRI .74***    
Step 2:  Demographic Variables  .75 .02 3.13* 
     Age -.08
†
    
     Income -.02    
     Education -.10*    
Step 3:  CBM Variables  .77 .02 3.19* 
     Risk -.03    
     Severity -.01    
     Coping Self-Efficacy -.18***    
     Reassurance-Seeking Behaviors .03    
Note.  N = 124. CBM = Cognitive-Behavioral Model; FCRI = Fear of Cancer Recurrence 
Inventory. 
†
 p < .10. *p < .05. **p < .01. ***p < .001. 
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Table 18. Hierarchical regression analyses predicting Fear of Cancer Recurrence Inventory 
scores at time 3 from demographic and Cognitive-Behavioral Model variables entered 
individually on the 3
rd
 step 
 
Predictor 
 
β 
 
R
2 
 
 
ΔR2 
 
 
ΔF 
 
Step 1:  Initial Score 
 
  
.73 
  
323.54*** 
     T1 FCRI .80***    
Step 2:  Demographic Variables  .75 .02 3.13* 
     Age -.07    
     Income -.04    
     Education -.11*    
Step 3:  CBM Variables     
     Risk .01 .75 .00 0.06 
     Severity .05 .75 .00 0.68 
     Coping Self-Efficacy -.17*** .77 .02 12.05** 
     Reassurance-Seeking Behaviors .00 .75 .00 0.00 
Note.  N = 124. CBM = Cognitive-Behavioral Model; FCRI = Fear of Cancer Recurrence 
Inventory. 
*p < .05. **p < .01. ***p < .001. 
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Table 19. Hierarchical regression analysis predicting worry and anxiety VAS scores at time 4 
from demographic and Cognitive-Behavioral Model variables 
 
Predictor 
 
β 
 
R
2 
 
 
ΔR2 
 
 
ΔF 
 
Step 1:  Initial Score 
 
  
.42 
   
81.79*** 
     T3 Combined VAS .63***    
Step 2:  Demographic Variables  .45 .03 1.89 
     Age .11    
     Income -.07    
     Education -.07    
Step 3:  CBM Variables  .45 .00 0.15 
     Risk .04    
     Severity -.05    
     Coping Self-Efficacy -.03    
     Reassurance-Seeking Behaviors .01    
Note.  N = 116. CBM = Cognitive-Behavioral Model; VAS = Visual Analogue Scale. 
*p < .05. **p < .01. ***p < .001. 
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Table 20. Hierarchical regression analyses predicting worry and anxiety VAS scores at time 4 
from demographic and Cognitive-Behavioral Model variables entered individually on the 3
rd
 
step 
 
Predictor 
 
β 
 
R
2 
 
 
ΔR2 
 
 
ΔF 
 
Step 1:  Initial Score 
 
  
.42 
  
81.79*** 
     T3 Combined VAS .63***    
Step 2:  Demographic Variables  .45 .03 1.89 
     Age .12    
     Income -.07    
     Education -.06    
Step 3:  CBM Variables     
     Risk .03 .45 .00 .20 
     Severity -.04 .45 .00 .24 
     Coping Self-Efficacy -.02 .45 .00 .06 
     Reassurance-Seeking Behaviors .00 .45 .00 .00 
Note.  N = 116. CBM = Cognitive-Behavioral Model; VAS = Visual Analogue Scale. 
*p < .05. **p < .01. ***p < .001. 
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Table 21. Hierarchical regression analyses predicting worry and anxiety VAS scores at time 6 
from demographic and Cognitive-Behavioral variables 
 
Predictor 
 
β 
 
 
R
2 
 
 
ΔR2 
 
 
ΔF 
 
Step 1:  Initial Score 
 
 
 
 
.29 
   
47.15*** 
     T4 Combined VAS        .45***    
Step 2:  Demographic Variables  .36 .05 5.86* 
     Income       -.25**    
     Education .13    
Step 3:  CBM Variables  .37 .01 0.98 
     Risk .06    
     Severity       -.05    
     Coping Self-Efficacy       -.14    
     Reassurance-Seeking Behaviors .07    
Note.  N = 118. CBM = Cognitive-Behavioral Model; VAS = Visual Analogue Scale. 
*p < .05. **p < .01. ***p < .001. 
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Table 22. Hierarchical regression analyses predicting worry and anxiety VAS scores at time 6 
from demographic and Cognitive-Behavioral Model variables entered individually on the 3
rd
 
step 
 
Predictor 
 
β 
 
 
R
2 
 
 
ΔR2 
 
 
ΔF 
 
Step 1:  Initial Score 
 
  
.29 
  
47.15*** 
     T4 Combined VAS .48***    
Step 2:  Demographic Variables  .36 .05 5.86* 
     Income -.27***    
     Education .13    
Step 3:  CBM Variables     
     Risk .08 .36 .00 1.08 
     Severity .03 .36 .00 0.15 
     Coping Self-Efficacy -.13
†
 .37 .01 2.86 
     Reassurance-Seeking Behaviors .05 .36 .00 0.36 
Note.  N = 118. CBM = Cognitive-Behavioral Model. VAS = Visual Analogue Scale. 
†
 p < .10. *p < .05. **p < .01. ***p < .001.
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Table 23. Unconditional growth curve models for worry and anxiety VAS over all study time points 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note.  N = 160. AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; -2LL. = Log likelihood (Deviance); 
Param. = Number of Parameters; VAS = Visual Analogue Scale. 
*Indicates a significant improvement in model fit over the previous model at the p < .05 level. 
a
Variance for linear slope for T1 to T3 was constrained to 0. 
b
Residual variances were set to equal 0 and variance for linear slope for T1 to T3 was constrained to 0. 
 
 
 
 
 
 
 
 
 
 
 
Models 
 
Param. 
 
 
ΔParam.  
 
-2LL 
 
Δ-2LL 
 
AIC 
 
BIC 
 
Linear Growth Curve 
 
11 
  
-3917.82 
  
7857.64 
 
7891.47 
 
a
Quadratic Growth Curve 
 
15 
 
4 
 
-3900.39 
 
17.43* 
 
7830.79 
 
7876.92 
 
b
Linear Piecewise Growth Curve  
 
12 
 
3 
 
-3891.60 
 
8.79* 
 
7807.21 
 
7844.11 
 
c
Piecewise Growth Curve  
with Linear Pre-Mammogram 
Segment and Quadratic Post-
Mammogram Segment  
 
 
11 
 
1 
 
-3856.30 
 
35.24* 
 
7734.72 
 
7768.54 
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Table 24. Growth mixture models 
 
Note.  N = 160. AIC = Akaike Information Criterion; BIC = Bayesian Information Criterion; -2LL. = Log likelihood (Deviance); 
Param. = Number of Parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Models 
 
Param. 
 
 
ΔParam.  
 
-2LL 
 
Δ-2LL 
 
AIC 
 
BIC 
 
Entropy 
 
1 Class 
 
11 
  
-3856.36 
  
7734.72 
 
7768.54 
 
 
 
2 Classes 
 
23 
 
     12 
 
-3683.64 
 
   172.72* 
 
7413.27 
 
7484.00 
 
0.961 
 
3 Classes 
 
32 
 
9 
 
-3643.61 
 
40.03* 
 
7351.22 
 
7449.62 
 
0.976 
 
4 Classes  
 
 
29 
 
3 
 
-3632.12 
 
11.49* 
 
7322.24 
 
7411.42 
 
0.897 
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Table 25. Sample description and univariate predictors of class membership 
 
 
Characteristic 
 
Total (N = 160) 
Fear of Recurrence Class  Univariate Logistic Regression 
Low (n = 40) High (n = 120)  OR 95% CI p-value 
Demographic Characteristics 
Age (years)        
   M (SD) 61.48 (9.60) 63.22 (9.01) 60.91 (9.79)  0.97 0.94, 1.01 .19 
Education        
   % college-educated 84.47 87.50 83.33  0.71 0.25, 2.05 .53 
Marital Status        
   % married 73.29 77.50 71.67  0.73 0.32, 1.70 .47 
Parent of a child        
   % parents 11.18 7.50 12.50  1.76 0.48, 6.43 .39 
Annual household income        
   % >$40,000 72.18 82.14 69.23  0.49 0.17, 1.40 .18 
 
Clinical Characteristics 
Disease Stage        
   % stage 0 or 1 72.05 72.50 71.67  0.96 0.43, 2.14 .92 
Treatment        
   % chemotherapy & 
radiation 
21.12 12.50 24.17  2.23 0.80, 6.22 .13 
   % chemotherapy 5.59 7.50 5.00  0.65 0.16, 2.72 .55 
   % radiation 58.49 67.50 55.93  0.61 0.29, 1.30 .20 
   % surgery only 14.47 12.50 14.41  1.18 0.41, 3.43 .76 
Surgery Type        
   % mastectomy 24.22 25.00 23.33  0.91 0.40, 2.10 .83 
Current hormone therapy        
   % yes 79.87 82.05 78.99  0.82 0.33, 2.08 .68 
Previous mammograms        
   % ≥ 1 post-treatment 74.53 80.00 72.50  0.66 0.28, 1.58 .35 
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Table 25 (Continued) 
 
 
Characteristic 
 
Total (N = 160) 
Fear of Recurrence Class  Univariate Logistic Regression 
Low (n = 40) High (n = 120)  OR 95% CI p-value 
Cognitive-Behavioral Model Variables 
Risk        
   M (SD) 33.28 (8.35) 27.55 (8.42) 35.10 (7.43)  1.13 1.07, 1.20 <.001 
Severity        
   M (SD) 22.01 (4.60) 20.63 (4.63) 22.43 (4.49)  1.09 1.01, 1.18 .03 
Treatment Efficacy Beliefs        
   M (SD) 15.20 (2.01) 15.35 (2.08) 15.14 (2.00)  0.95 0.80, 1.13 .57 
Coping Self-Efficacy Beliefs        
   M (SD) 108.09 (21.49) 117.63 (16.84) 104.88 (22.06)  0.97 0.95, 0.99 .002 
Reassurance-Seeking 
Behaviors 
       
   M (SD)   6.34 (1.80)   5.78 (1.69)   6.53 (1.81)  1.31 1.03, 1.66 .03 
 
 
Note.  CI = Confidence Interval; M = Mean; OR = Odds Ratio; SD = Standard Deviation. 
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Table 26. Multivariate predictors of class membership 
 
Variable 
 
 
OR 
 
95% CI 
 
p-value 
 
Risk 
 
1.13 
 
1.06, 1.20 
 
<.001 
 
Severity 
 
0.96 
 
0.87, 1.06 
 
.45 
 
Coping Self-Efficacy Beliefs 
 
0.98 
 
0.95, 1.00 
 
.05 
 
Reassurance-Seeking Behaviors 
 
 
1.36 
 
1.04, 1.77 
 
.03 
 
Note.  CI = Confidence Interval; OR = Odds Ratio. 
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DISCUSSION 
 
FCR demonstrated predictable changes over time before and after follow-up surveillance 
mammograms in breast cancer survivors.  As predicted, a significant reduction in FCR was 
observed from immediately before to immediately after negative mammogram results were 
communicated.  There was also partial support for the hypothesis that FCR increases before the 
mammogram and increases over the month following the disclosure of mammogram results.  
Contrary to expectations, CBM variables did not reliably predict change in FCR over time when 
controlling for previous FCR, but the model was generally predictive of distinct class trajectories 
in FCR over time.  The results of the present study are considered in more detail below, along 
with limitations, implications, and future directions.   
Change in Fear of Cancer Recurrence over Time 
The first aim of the present study was to determine if FCR in breast cancer survivors 
fluctuated significantly before and after mammography screening.  Hypothesis 1, which stated 
that FCR would increase in the month prior to the mammogram, was partially supported as 
scores on the CWS demonstrated a significant increase leading up to the mammogram 
appointment.  However, other measures (i.e., combined VAS measure) revealed no significant 
change leading up to the mammogram or demonstrated a significant decline (i.e., FCRI).  These 
findings suggest that the various measures used may be tapping different aspects of FCR.  The 
CWS assesses the amount of thoughts, worries, mood disturbance, and daily activity disturbance 
related to worries about cancer recurrence in the past week.  It focuses on the frequency of these 
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thoughts and the frequency of the interference of these thoughts.  As noted above, women with a 
history of breast cancer reported increasing thoughts, concerns, and related interference from 
these concerns leading up to their mammogram.  However, there was no change in the VAS 
measures of anxiety and worry about recurrence prior to the mammogram.  Rather than assess 
frequency, these state measures assess the magnitude of the anxiety and worry being experienced 
at that moment.  It may be that the frequency of thoughts and the associated interference 
increases prior to the mammogram, but that the intensity of the anxiety and worry remains 
largely the same during this time period.  Finally, the FCRI addresses a longer period of time 
(e.g., the past month), and so participants were reporting their FCR for the two months prior to 
the mammogram when they completed this measure at T1 and T3.  It is not clear why a 
statistically significant decline occurred over this time period, but it may be that reports from the 
past month are less accurate given the heavy reliance on participants’ recall of FCR.  It should 
also be noted that, while statistically significant, the observed p-value was on the margin of 
significance (p = .05) and the decline in FCRI scores represented a small change in the degree of 
FCR reported between these two time points. 
The clearest and most dramatic change in anxiety and worry about recurrence occurred 
during the immediate pre-mammogram to immediate post-mammogram assessment period.  As 
hypothesized (Hypothesis 2), participants reported a significant decline in FCR as measured by 
the VAS measures as soon as they were given results from their physician that demonstrated no 
evidence that the cancer had recurred.  These results are consistent with other research evaluating 
the impact of negative medical test results on patients with various health statuses; medical 
exams that reveal no signs of disease or disorder help to alleviate health-related and general 
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anxiety in the short-term (Donkin et al., 2006; Lucock et al., 1997; Rimes & Salkovskis, 2002; 
Quadri & Vakil, 2003).   
Following the mammogram, additional assessments revealed significant linear and 
quadratic increases in anxiety and worry about recurrence on the VAS measures.  These findings 
support the hypothesis (Hypothesis 3) that within one month post-mammogram participants 
would experience an increase in FCR levels.  However, when evaluating past week cancer 
recurrence worry using the CWS during this time segment, there was no significant change over 
time.  It is important to note that the CWS was administered at T1, T2, T3, T5, and T6, but was 
not collected during the immediate post-mammogram assessment point (T4).  Scores on the VAS 
measures were at their lowest at T4, but then leveled off from T5 to T6, meaning that there were 
smaller changes in FCR after the first week post-mammogram.  Hence, it may be the case that 
the significant increase in FCR happens sooner than the first week post-mammogram, which 
could explain the lack of change for the CWS.  This pattern is similar to results of other studies 
of health anxiety after a medical exam such as gastroscopy, stress tests in healthy patients, or 
routine oncology follow-up visits in survivors of various cancers.  The most dramatic effect of 
reassuring results occurred within the days after receipt of the results, with health anxiety and 
worry levels rather quickly increasing and reassurance decreasing back to baseline levels 
(Donkin et al., 2006; Lampic et al., 1994; Lucock et al., 1997).  Again, the present study was 
consistent with the previous research demonstrating a very brief reprieve from health-related and 
general anxiety granted by a negative medical test result (Donkin et al., 2006; Lampic et al., 
1994; Lucock et al., 1997). 
When general state anxiety as measured by the brief STAI was examined, similar patterns 
as for FCR emerged but with some key differences noted.  STAI scores demonstrated both 
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significant linear and quadratic increases leading up to the mammogram, followed by a 
significant decrease immediately post-mammogram, and then no change in the month after the 
mammogram.  The differences in the observed patterns between general state anxiety and the 
state FCR measures demonstrate that FCR is distinct from general state anxiety.  While 
participants endorsed no change in FCR magnitude leading up to the mammogram as measured 
by the combined VAS measure, there were significant increases in STAI scores prior to the 
mammogram with a steeper incline in STAI scores as the appointment day approached.  The 
brief STAI assesses feeling calm, tense, upset, relaxed, content, and worried but did not provide 
a context for the anxiety levels experienced.  It may be that FCR magnitude does not vary during 
this time (i.e., women do not suddenly report changes in anxiety and worry about recurrence 
when they have received no new information or input from physicians), but the increase in cues 
related to cancer including reminders about their impending appointment may trigger some 
generalized anxiety.   
When reassurance was assessed post-mammogram, the significant increase in worry and 
anxiety about recurrence on the VAS measures was matched with a significant decline in the 
degree to which participants reported feeling reassured by their mammogram.  These findings 
add to the reliability of the finding from this and previous studies that reassurance post-
mammogram is relatively brief and short-lived (Donkin et al., 2006; Lampic et al., 1994; Lucock 
et al., 1997). 
Taken together across all study time points, the longitudinal patterns observed support 
and extend qualitative studies in which patients report that follow-up appointments and 
surveillance cancer screenings following completion of cancer treatment can trigger heightened 
FCR (Brook, 2011; Horlick-Jones, 2011; Okazaki et al., 2009; Thompson et al., 2010).  The 
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overall patterns of FCR, state anxiety, and reassurance before and after the mammogram were 
also consistent with previous studies of health anxiety and reassurance from medical 
examinations that evaluated both cancer patients returning for medical follow-up visits and 
patients with no history of cancer receiving gastroscopy, endoscopy, or stress test results 
(Donkin et al., 2006; Lampic et al., 1994; Lucock et al., 1997; Quadri & Vakil, 2003).  This 
finding bolsters the idea that FCR can be conceptualized as a subset of health anxiety, as patients 
with or without a medical condition appear to have similar patterns of reactions to medical tests 
as breast cancer survivors do when undergoing mammograms (Salkovskis & Warwick, 1986; 
Salkovskis & Warwick, 2001; Warwick, 1989; Warwick & Salkovskis, 1990). 
Predicting Change in Fear of Cancer Recurrence over Time 
The second aim evaluated whether the CBM could be used to predict the changes 
observed in FCR.  Cross-sectional univariate analyses revealed that CBM variables were related 
to FCR at each time point in the predicted directions, with the notable exception of treatment 
efficacy beliefs.  The lack of findings for this variable may be due to how it was measured in the 
present study.  In this study, participants simply rated how effective they believed various 
treatments could be for reducing risk of recurrence.  Overall, patients reported little variability in 
these beliefs; they generally believed that most treatments could be effective.  However, it is not 
clear from this measure how participants viewed their own treatment efficacy.  Perhaps results 
would vary if alternative items were used that were more sensitive to patient beliefs about 
treatment efficacy, especially if assessing patient beliefs about their own treatment efficacy, 
rather than general agreement or disagreement that various treatments can effectively reduce risk 
of cancer recurrence.  It may be that personal treatment efficacy beliefs would be more variable 
and more likely to be associated with FCR than generic treatment efficacy beliefs. 
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The hypothesis that the increases in FCR pre-mammogram could be predicted by CBM 
variables (Hypothesis 4) was partially supported.  When accounting for relevant clinical and 
demographic characteristics, at least one CBM variable accounted for additional unique variance 
in FCR during the time period prior to the mammogram depending on the specific outcome 
measure.  When predicting change in CWS scores, greater severity and greater reassurance-
seeking behaviors predicted greater increases in FCR.  However, only greater reassurance-
seeking behaviors independently predicted increases in FCR prior to the mammogram.  This 
finding is consistent with the Thewes et al. (2012) study, which found that patients who engaged 
in more self-exams and went to more unscheduled medical visits to discuss FCR (examples of 
reassurance-seeking behaviors) reported higher FCR levels than those who did not.  For analyses 
predicting change in FCRI scores, both education and coping self-efficacy (i.e., the degree of 
confidence that one can cope successfully with the tasks associated with a possible cancer 
recurrence), were negatively associated with FCRI scores immediately prior to the mammogram 
when controlling for initial FCRI scores.  Research examining the role of general coping and 
cancer-related coping self-efficacy has found similar relationships. Specifically, greater coping 
self-efficacy has been found to be related to lower FCR in cross-sectional studies of breast 
cancer patients in the year after diagnosis and up to eight years post-diagnosis (Melchior, 
Buscher, Thoren, Grochocka, Koch, & Watzke, 2011; Ziner, Sledge, Bell, Johns, Miller, & 
Champion, 2012).  In the present study, baseline cancer-related coping self-efficacy predicted 
later FCRI scores over and above the initial FCRI scores, while more general self-efficacy 
measures for coping with stressful situations did not predict FCR when controlling for initial 
values one year prior (Melchior et al., 2011).  These findings indicate that beliefs about cancer-
related coping self-efficacy are predictive of FCR, but general self-efficacy beliefs are not. 
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The hypothesis that the decreases in FCR from immediately pre-mammogram to 
immediately post-mammogram could be predicted by CBM variables (Hypothesis 5) was not 
supported.  The addition of the CBM variables did not predict the significant declines in the 
combined VAS measure observed immediately after the mammogram results were discussed 
with the physician.  The only significant predictor in this model was the initial combined VAS 
measure at just prior to the mammogram.  This result can be interpreted as the effect of the 
reporting of good results being so strong and universal for the majority of patients that there was 
not sufficient variability in the pattern available to be predicted by CBM variables.  It suggests 
that the vast majority of patients experienced a reduction in FCR, no matter their own clinical or 
demographic characteristics, or individual cognitions and behaviors. 
Similarly, the hypothesis that the increases in FCR post-mammogram could be predicted 
by CBM variables (Hypothesis 6) was not supported.  The significant increases evident on the 
combined VAS measure during the post-mammogram time period were not influenced by 
individual variability in CBM variables.  However, analyses did reveal that lower income 
participants reported larger increases on the combined VAS measure during the month following 
the mammogram.  No other clinical or demographic variables were related to changes on the 
combined VAS measure.  It appears that the passage of time and initial combined VAS measure 
levels are the best predictors of the eventual increases in scores back to baseline levels. 
In summary, while CBM variables were good predictors of FCR cross-sectionally, few 
CBM variables were predictive of the changes in FCR over time.  Initial FCR was a consistently 
good predictor of later FCR in all time segments across measures, suggesting that patients who 
experience higher levels will tend to report higher levels over time and across different situations 
compared to other patients.  This finding is consistent with the findings from previous 
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longitudinal studies that found evidence for stability in FCR over time (Ghazali, Cadwallader, 
Lowe, Humphris, Ozakinci, & Rogers, 2013; Humphris et al., 2003; Humphris & Rogers, 2004; 
Llewellyn et al., 2008; Stanton et al., 2002).  Few demographic characteristics and no clinical 
characteristics were related to FCR either cross-sectionally or longitudinally, which fits with 
results of previous studies which also did not find relationships with these variables (see Crist & 
Grunfeld, 2013 and Koch, Jansen, Brenner, & Arndt, 2013 for helpful reviews of demographic 
and clinical characteristics related to FCR).  
Individual Differences in Fear of Cancer Recurrence Trajectories over Time 
The exploratory analyses evaluated whether distinct classes of patients who experienced 
unique patterns of change in FCR existed.  Based on growth mixture modeling, two classes were 
identified:  the first class resembled the overall mean pattern observed for the overall sample and 
the second class represented a subgroup of patients who experienced the same pattern with both 
lower overall levels of FCR and more gradual slopes over time.  The first class included three 
quarters of the study sample and appeared to capture the prototypical trajectory for FCR before 
and after a mammogram.  While variability remained in this group, no consistent patterns 
emerged within this class that would justify additional subclasses.  The second class, which 
included approximately a quarter of the participants in this study, demonstrated relatively little 
variability between subjects. 
Examination of predictors revealed that demographic and clinical characteristics were not 
significantly related to class membership.  However, the following CBM variables were 
independently predictive of class membership:  perceived risk, coping self-efficacy, and 
reassurance-seeking behaviors.  Hence, the CBM has utility in predicting which breast cancer 
survivors are likely to experience heightened FCR.   
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Strengths and Limitations 
There are many notable strengths of the current study.  First, this was the first prospective 
investigation of FCR before and after a medically significant event in the survivorship phase.  
Second, various types of FCR measures were utilized allowing for examination of the magnitude 
and frequency of cancer-related worry, anxiety, and fears related to cancer recurrence.  Third, 
both within- and between-subject differences in FCR were examined along with their 
relationships to various demographic, clinical, and psychosocial characteristics.  Fourth, distinct 
trajectories were evaluated using growth mixture modeling.  Finally, the study tested the utility 
of an established theoretical model of health anxiety to determine to what degree FCR can be 
predicted by a set of modifiable cognitive and behavioral factors.  
Several important limitations must also be noted.  First, as has been pointed out in several 
previous studies of FCR (Petzel et al., 2012; Simard & Savard, 2009; Simard et al., 2010; 
Thewes et al., 2012), it is difficult to determine whether study participants adequately represent 
the patient population from which they are drawn.  Only 51% of invited women chose to 
participate.  Based on anecdotal evidence, several women noted that they were declining 
participation because they were too fearful and did not want additional reminders of cancer or 
the possibility of a recurrence.  Consequently, the possibility that study findings may be 
influenced by participation bias cannot be ruled out.  Second, the study sample included only 
women previously diagnosed with early-stage breast cancer and so the study findings cannot be 
generalized to other groups of cancer patients.  Third, the primary outcome variable was the 
combined VAS measure, which has not been previously validated for assessing FCR.  However, 
this measure demonstrated good psychometric properties in the current sample and was highly 
correlated to the other more established measures of FCR used.  Fourth, the evaluation of patient 
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treatment efficacy beliefs focused on general beliefs about various treatments, but not on beliefs 
about treatments previously received.  Alternative measures which assess patient’s perceptions of 
efficacy of their own treatment may be more predictive of FCR than our more generic cancer 
treatment efficacy beliefs scale.  Finally, it is important to note that lack of significant findings 
for change over time does not necessarily imply stability in FCR over time.  It is more 
appropriate to interpret those findings as lack of systematic change over time across patients as 
individual patterns of change were highly variable, but not always in similar directions, across 
participants. 
Theoretical Implications 
The study findings demonstrated that FCR changes over time in a predictable fashion 
before and after surveillance screening exams.  Furthermore, plotting individual combined VAS 
scores over time reveals a very broad range of trajectories experienced by participants in this 
study.  Hence, it is important to recognize that, while two classes were identified in the models, 
momentary concerns about recurrence do demonstrate substantial variability that is difficult to 
predict consistently both within and across patients.  This between-person variability fits with 
patient accounts of the so-called “Sword of Damocles” phenomenon associated with FCR; worry 
and anxiety about recurrence may loom for most, but these concerns tend to become more 
prominent or bothersome depending on circumstances which may vary greatly between patients 
(Cesario, Nelson, Broxson, & Cesario, 2010; Koch et al., 2013; Lee-Jones, Humphris, Dixon, & 
Hatcher, 1997; McCaughan, Prue, Parahoo, McIlfatrick, & McKenna, 2012).   
The present study determined that CBM variables were related to FCR cross-sectionally 
and predicted class membership for varying trajectories in FCR over time.  When CBM variables 
were used as predictors of change for each time segment, there was limited support for the 
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theoretical model.  However, when these same variables were used to predict the high-FCR and 
low-FCR classes, the CBM variables were the best predictors over and above other individual 
characteristics.  These findings demonstrate the utility of using growth mixture modeling when 
evaluating FCR and theoretical models for understanding it.   
While the current study identified several predictors of heightened FCR, additional 
predictors of change in FCR over time and class membership should be evaluated in future 
research.  Dispositional variables such as neuroticism or optimism, and coping styles, and 
specific triggers of FCR, such as somatic symptoms, exposure to others’ illness, death, or cancer, 
and cancer-related anniversaries, have been found to be related to FCR in previous cross-
sectional studies (Crist & Grunfeld, 2013; Koch et al., 2013) and may predict differences in 
trajectories over time.  Finally, this study demonstrated varying patterns between FCR and 
general state anxiety.  Future research should further evaluate to what extent FCR and other 
forms of anxiety, especially health-related anxiety, may differ. 
Clinical Implications 
This study has several implications for clinical practice.  Overall, women with a history 
of breast cancer report low to moderate FCR even during the time period surrounding follow-up 
surveillance cancer screening.  Mammogram results do appear to provide a dramatic reduction in 
FCR for the majority of patients and reassurance from these examinations remains relatively 
high during the month after the appointment.  However, the reduction in FCR is brief and 
patients can be told that repeated examination is not the best method for reducing their own FCR 
for the long-term and that such reassurance-seeking behaviors are related to greater FCR.   
Providers should also be aware that those women who report low FCR are likely to 
continue to report low levels and women reporting high FCR are likely to continue to report high 
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levels and have steeper changes in their FCR before and after a mammogram appointment, even 
if provided with negative results, as evidenced by the finding that initial FCR was always the 
strongest predictor of later FCR.  Examination of the subclasses from the growth mixture models 
revealed a sizable minority of patients who likely would not need or request services to help 
them cope with or reduce FCR.  However, the majority of patients would likely benefit from 
some sort of psychoeducation about FCR and what may make a person more at risk of 
developing distressing FCR levels.   
In addition, several modifiable characteristics related to the experience of heightened 
FCR were identified, which may help inform future interventions designed to reduce FCR in 
patients with a history of cancer.  The findings suggest that future research should test the 
efficacy of CBM-informed interventions in reducing FCR, especially those that focus on 
providing patients with more accurate recurrence risk perceptions, reducing reassurance-seeking 
behaviors such as excessive self-exams, and improving self-efficacy for dealing with the 
possibility of a recurrence.  There are several interventions which already target at least some of 
these factors, such as reassurance-seeking behaviors (Bailey, Mishel, Belyea, Stewart, & Mohler, 
2004; Humphris & Ozakinci, 2008) and risk perceptions (Humphris et al., 2008).  Interventions 
might also focus on social modeling from patients who are successfully coping with recurrence 
(Stanton et al., 2005) and teaching patients new skills for handling medical or interpersonal 
situations associated with distress to increase coping self-efficacy (Marks & Allegrante, 2005).  
Future research should evaluate whether all of these characteristics (higher perceived risk, lower 
coping self-efficacy, and greater reassurance-seeking behaviors) need to be addressed to reduce 
reported FCR or if targeting either one or a subset of these characteristics is effective in treating 
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FCR.  CBM variables should also be evaluated as possible underlying mechanisms of change in 
such interventions.   
Summary and Conclusions 
This study represents the first theory-driven, prospective longitudinal assessment of FCR 
focused around a medically meaningful event.  Across time, FCR fluctuated in the expected 
directions, with increases observed prior to the mammogram, a significant decline observed 
immediately following receipt of results, and a gradual, but significant increase in FCR and 
decrease in reassurance observed during the month following the mammogram.  The CBM did 
not significantly predict change in FCR over time, but certain variables did predict fluctuations 
including coping-self efficacy and perceived risk.  Moreover, growth mixture models revealed 
high-FCR and low-FCR classes which were predicted by the CBM.  Future research should 
examine the utility of the CBM for informing FCR interventions for patients experiencing 
distressing or excessive FCR.    
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